<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">66596</article-id><article-id pub-id-type="doi">10.7554/eLife.66596</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Matriptase activation of Gq drives epithelial disruption and inflammation via RSK and DUOX</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-223117"><name><surname>Ma</surname><given-names>Jiajia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223118"><name><surname>Scott</surname><given-names>Claire A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223119"><name><surname>Ho</surname><given-names>Ying Na</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-240285"><name><surname>Mahabaleshwar</surname><given-names>Harsha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223120"><name><surname>Marsay</surname><given-names>Katherine S</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223121"><name><surname>Zhang</surname><given-names>Changqing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223122"><name><surname>Teow</surname><given-names>Christopher KJ</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223123"><name><surname>Ng</surname><given-names>Ser Sue</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223124"><name><surname>Zhang</surname><given-names>Weibin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-16841"><name><surname>Tergaonkar</surname><given-names>Vinay</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223125"><name><surname>Partridge</surname><given-names>Lynda J</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223126"><name><surname>Roy</surname><given-names>Sudipto</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-11382"><name><surname>Amaya</surname><given-names>Enrique</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-70828"><name><surname>Carney</surname><given-names>Tom J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2371-1924</contrib-id><email>tcarney@ntu.edu.sg</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Lee Kong Chian School of Medicine, Experimental Medicine Building, Yunnan Garden Campus, 59 Nanyang Drive, Nanyang Technological University</institution><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff><aff id="aff2"><label>2</label><institution>Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research)</institution><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff><aff id="aff3"><label>3</label><institution>Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester</institution><addr-line><named-content content-type="city">Manchester</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution>Department of Molecular Biology and Biotechnology, University of Sheffield</institution><addr-line><named-content content-type="city">Sheffield</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution>Department of Biological Sciences, National University of Singapore</institution><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff><aff id="aff6"><label>6</label><institution>Department of Pediatrics, Yong Loo Ling School of Medicine, National University of Singapore</institution><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Reviewing Editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Senior Editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>24</day><month>06</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e66596</elocation-id><history><date date-type="received" iso-8601-date="2021-01-15"><day>15</day><month>01</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-06-23"><day>23</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Ma et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Ma et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-66596-v2.pdf"/><abstract><p>Epithelial tissues are primed to respond to insults by activating epithelial cell motility and rapid inflammation. Such responses are also elicited upon overexpression of the membrane-bound protease, Matriptase, or mutation of its inhibitor, Hai1. Unrestricted Matriptase activity also predisposes to carcinoma. How Matriptase leads to these cellular outcomes is unknown. We demonstrate that zebrafish <italic>hai1a</italic> mutants show increased H<sub>2</sub>O<sub>2</sub>, NfκB signalling, and IP<sub>3</sub>R -mediated calcium flashes, and that these promote inflammation, but do not generate epithelial cell motility. In contrast, inhibition of the Gq subunit in <italic>hai1a</italic> mutants rescues both the inflammation and epithelial phenotypes, with the latter recapitulated by the DAG analogue, PMA. We demonstrate that <italic>hai1a</italic> has elevated MAPK pathway activity, inhibition of which rescues the epidermal defects. Finally, we identify RSK kinases as MAPK targets disrupting adherens junctions in <italic>hai1a</italic> mutants. Our work maps novel signalling cascades mediating the potent effects of Matriptase on epithelia, with implications for tissue damage response and carcinoma progression.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Cancer occurs when normal processes in the cell become corrupted or unregulated. Many proteins can contribute, including one enzyme called Matriptase that cuts other proteins at specific sites. Matriptase activity is tightly controlled by a protein called Hai1. In mice and zebrafish, when Hai1 cannot adequately control Matriptase activity, invasive cancers with severe inflammation develop. However, it is unclear how unregulated Matriptase leads to both inflammation and cancer invasion.</p><p>One outcome of Matriptase activity is removal of proteins called Cadherins from the cell surface. These proteins have a role in cell adhesion: they act like glue to stick cells together. Without them, cells can dissociate from a tissue and move away, a critical step in cancer cells invading other organs. However, it is unknown exactly how Matriptase triggers the removal of Cadherins from the cell surface to promote invasion.</p><p>Previous work has shown that Matriptase switches on a receptor called Proteinase-activated receptor 2, or Par2 for short, which is known to activate many enzymes, including one called phospholipase C. When activated, this enzyme releases two signals into the cell: a sugar called inositol triphosphate, IP3; and a lipid or fat called diacylglycerol, DAG. It is possible that these two signals have a role to play in how Matriptase removes Cadherins from the cell surface.</p><p>To find out, Ma et al. mapped the effects of Matriptase in zebrafish lacking the Hai1 protein. This revealed that Matriptase increases IP3 and DAG levels, which initiate both inflammation and invasion. IP3 promotes inflammation by switching on pro-inflammatory signals inside the cell such as the chemical hydrogen peroxide. At the same time, DAG promotes cell invasion by activating a well-known cancer signalling pathway called MAPK. This pathway activates a protein called RSK. Ma et al. show that this protein is required to remove Cadherins from the surface of cells, thus connecting Matriptase’s activation of phospholipase C with its role in disrupting cell adhesion.</p><p>An increase in the ratio of Matriptase to HAI-1 (the human equivalent of Hai1) is present in many cancers. For this reason, the signal cascades described by Ma et al. may be of interest in developing treatments for these cancers. Understanding how these signals work together could lead to more direct targeted anti-cancer approaches in the future.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Matriptase</kwd><kwd>RSK</kwd><kwd>inflammation</kwd><kwd>Hai1</kwd><kwd>Par2</kwd><kwd>Gq</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001459</institution-id><institution>Ministry of Education - Singapore</institution></institution-wrap></funding-source><award-id>2015-T1-001-035</award-id><principal-award-recipient><name><surname>Ma</surname><given-names>Jiajia</given-names></name><name><surname>Carney</surname><given-names>Tom J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001459</institution-id><institution>Ministry of Education - Singapore</institution></institution-wrap></funding-source><award-id>MOE2016-T3-1-005</award-id><principal-award-recipient><name><surname>Mahabaleshwar</surname><given-names>Harsha</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The serine protease Matriptase orchestrates simultaneous epithelial cell motility and inflammation in pathological states through respective activation of the MAPK pathway and generation of hydrogen peroxide.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The transmembrane serine protease, Matriptase, encoded by the <italic>ST14</italic> gene, has potent oncogenic properties and is consistently dysregulated in human carcinomas. Overexpression of Matriptase in the mouse epidermis leads to epidermal papillomas, ulcerative and invasive carcinomas, and inflammation (<xref ref-type="bibr" rid="bib31">List et al., 2005</xref>; <xref ref-type="bibr" rid="bib34">Martin and List, 2019</xref>). These effects of Matriptase are mitigated by a cognate serine protease inhibitor, HAI-1. Clinically, an increase in the Matriptase:HAI-1 ratio has been found in a range of tumours and is predictive of poor outcome (<xref ref-type="bibr" rid="bib34">Martin and List, 2019</xref>). Loss of mouse Hai1 leads to epidermal and intestinal barrier defects, epithelial inflammation, and failure of placental labyrinth formation, which are all due to unrestricted Matriptase activity (<xref ref-type="bibr" rid="bib27">Kawaguchi et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Nagaike et al., 2008</xref>; <xref ref-type="bibr" rid="bib60">Szabo et al., 2007</xref>). The response of epithelia to unregulated Matriptase activity appears conserved across vertebrates. Mutation of the zebrafish orthologue, Hai1a, also results in epidermal defects, including loss of membrane E-cadherin, aberrant mesenchymal behaviour of keratinocytes, which form cell aggregations over the body and loss of fin fold integrity. The epidermis also displays sterile inflammation and is invaded by highly active neutrophils. Genetic ablation of the myeloid lineage demonstrated that the keratinocyte phenotypes are not a consequence of the inflammation (<xref ref-type="bibr" rid="bib8">Carney et al., 2007</xref>). The strong <italic>hai1a<sup>fr26</sup></italic> allele is embryonic lethal, dying within the first week, whilst the more mild allele, <italic>hai1a<sup>hi2217</sup></italic>, is semi-viable, with epithelial defects resolved through sphingosine-1-phosphate-mediated entosis and cell extrusion (<xref ref-type="bibr" rid="bib6">Armistead et al., 2020</xref>). All <italic>hai1a</italic> mutant phenotypes can be ameliorated by reduction of Matriptase levels (<xref ref-type="bibr" rid="bib8">Carney et al., 2007</xref>; <xref ref-type="bibr" rid="bib35">Mathias et al., 2007</xref>).</p><p>Due to the clinical implications of its dysregulation, the signalling pathways activated pathologically by Matriptase are of interest. The G-protein-coupled receptor, proteinase-activated receptor-2 (Par2), is essential for the oncogenic and inflammatory effects of uninhibited Matriptase in zebrafish and mouse (<xref ref-type="bibr" rid="bib48">Sales et al., 2015</xref>; <xref ref-type="bibr" rid="bib53">Schepis et al., 2018</xref>). Par2 is directly activated by Matriptase proteolysis and signals through a number of heterotrimeric Gα protein subunits. Early studies in keratinocytes linked Par2 activation with intracellular Ca<sup>++</sup> mobilisation via phospholipase C, thus implicating Gq subunit as the canonical target (<xref ref-type="bibr" rid="bib52">Schechter et al., 1998</xref>). Alternate Gα subunits, including Gi, Gs, and G12/13, are now known to also be activated by Par2 (<xref ref-type="bibr" rid="bib69">Zhao et al., 2014</xref>). Par2 displays biased agonism, and the logic of the pathway utilised depends on cell context and the activating protease. In vitro experiments using HEK293 cells implicated both Par2 and Gi in Matriptase-mediated Nfκb pathway activation (<xref ref-type="bibr" rid="bib48">Sales et al., 2015</xref>). Whilst this explains the inflammatory phenotype of uninhibited Matriptase, it does not address whether Par2 promotes carcinoma phenotypes directly in keratinocytes in vivo. In zebrafish, as the keratinocyte defects are not dependent on inflammation, but are dependent on Par2, it is likely that there is a direct effect of Par2 on promoting keratinocyte motility. Par2 can also transactivate EGFR through an unknown mechanism, and inhibition of EGFR alleviates certain basal keratinocyte phenotypes of zebrafish <italic>hai1a</italic> mutants (<xref ref-type="bibr" rid="bib53">Schepis et al., 2018</xref>). Thus, the identity, contribution, and interactions of the pathways downstream of Matriptase and Par2 remain unclear. Here through use of the zebrafish <italic>hai1a</italic> mutant, we comprehensively map the essential pathways downstream of zebrafish Matriptase and Par2, leading to inflammation and epithelial disruption.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Increased hydrogen peroxide and calcium flashes contribute to inflammation in <italic>hai1a</italic> mutants</title><p>Neutrophils in <italic>hai1a</italic> embryos invade the epidermis, are highly motile, but move randomly (<xref ref-type="bibr" rid="bib8">Carney et al., 2007</xref>; <xref ref-type="bibr" rid="bib35">Mathias et al., 2007</xref>; <xref ref-type="fig" rid="fig1">Figure 1A–E</xref>, <xref ref-type="video" rid="video1">Video 1</xref>). To establish the nature of their stimulus, we tested if neutrophils in <italic>hai1a</italic> altered their behaviour in the presence of a large fin wound. In wild-type larvae, neutrophils were recruited from a great distance and tracked to the wound with high directionality. However, neutrophils in the <italic>hai1a</italic> mutant appeared largely apathetic to the wound and remained migrating randomly. There was a mild increase in neutrophil speed in <italic>hai1a</italic> larvae following wounding, indicating that they retain capacity to respond to additive stimuli (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–D</xref>, <xref ref-type="video" rid="video2">Video 2</xref>). Co-labelling of basal keratinocyte nuclei (using TP63 immunostaining), neutrophils (<italic>Tg(fli1:EGFP)<sup>y1</sup></italic> transgenic), and TUNEL labelling of apoptotic cells highlighted that whilst the epidermis of <italic>hai1a</italic> mutants, unlike WT, had regions of apoptosis at 24hpf (arrowhead, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E, F</xref>), neutrophils were not associated, but rather found at nascent TUNEL-negative aggregates of basal keratinocytes (arrow). We conclude that epidermal cell death does not directly contribute to inflammation and that the effector stimulating neutrophils in <italic>hai1a</italic> mutants is as, or more, potent as that of wounds.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The epidermis of <italic>hai1a</italic> mutants displays elevated hydrogen peroxide.</title><p>(<bold>A, B</bold>) Projected confocal images showing neutrophils populate the tail of <italic>hai1a<sup>hi2217</sup></italic> mutants (<bold>B</bold>) but just the vasculature of WT (<bold>A</bold>) at 4dpf labelled by the <italic>Tg(mpx:EGFP)<sup>i114</sup></italic> line. Fin extremity outlined in white. (<bold>C</bold>) Neutrophils move significantly faster in <italic>hai1a<sup>hi2217</sup></italic> than WT. n = 15; t-test; ***p&lt;0.001. (<bold>D, E</bold>) Tracks of neutrophil migration taken from <xref ref-type="video" rid="video1">Video 1</xref> in WT (<bold>D</bold>) and <italic>hai1a<sup>hi2217</sup></italic> (<bold>E</bold>). (<bold>F</bold>) Schematic of the Hai1a protein with protein domains given, signal peptide as purple line and transmembrane domain as grey line. Location and nature of the <italic>fr26</italic> and two <italic>dandruff</italic> alleles, <italic>ti251</italic> and <italic>t419</italic> given. (<bold>G</bold>) Selected region of 2D gel of protein extracted from 24hpf embryos for <italic>hai1a<sup>t419</sup></italic> (left) or <italic>hai1a<sup>ti251</sup></italic> (right) in red, superimposed over WT protein samples (green in both). The shift in pI of peroxiredoxin4 in both alleles is indicated with an arrow. (<bold>H, I</bold>) Projected lateral confocal views of pentafluorobenzenesulfonyl fluorescein (PFBSF) staining of WT (<bold>H</bold>) and <italic>hai1a<sup>ti251/hi2217</sup></italic> (<bold>I</bold>) tail fins at 48hpf. (<bold>J</bold>) Box and whiskers plot of PFBSF fluorescent staining intensity of WT and <italic>hai1a<sup>fr26</sup></italic> mutants at 48hpf in trunk and tail. n = 9; t-test ***p&lt;0.001. (<bold>K, L</bold>) Projected lateral confocal views of PFBSF staining of WT (<bold>K</bold>) and <italic>hai1a<sup>hi2217</sup></italic> (<bold>L</bold>) at 16hpf. Scale bars: (<bold>B</bold>, <bold>I</bold>, <bold>L</bold>) = 100 µm.</p><p> <supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>2D proteomics protein ID report list of the spot identities with significant ratio changes.</title></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-66596-fig1-data1-v2.xls"/></supplementary-material> </p><p> <supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>2D proteomics protein ratio changes for each of the protein spots identified as significantly changed.</title></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-66596-fig1-data2-v2.xls"/></supplementary-material> </p><p> <supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>2D proteomics top 50 proteins significantly changed in <italic>hai1a</italic> mutants.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-66596-fig1-data3-v2.pdf"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>The epidermis of <italic>hai1a</italic> mutants displays elevated hydrogen peroxide.</title><p>(<bold>A, B</bold>) Tracks of neutrophil migration taken from <xref ref-type="video" rid="video2">Video 2</xref> in WT (<bold>A</bold>) and <italic>hai1a<sup>hi2217</sup></italic> (<bold>B</bold>) from immediately after wounding tail fin at indicated site. (<bold>C, D</bold>) Graph of neutrophil speed (<bold>C</bold>) and distance travelled (<bold>D</bold>) before and after wounding in WT and <italic>hai1a<sup>hi2217</sup></italic>. Neutrophils in wounded WT move as fast as unwounded <italic>hai1a</italic> mutants. Wounding <italic>hai1a</italic> mutants accelerates neutrophils. n = 15; ANOVA with Bonferroni post-test ***p&lt;0.001, **p&lt;0.01. (<bold>E, F</bold>) Projected confocal images showing neutrophils (green, labelled by <italic>Tg(fli1:egfp)<sup>y1</sup></italic> transgenic line) are not attracted to regions of apoptosis (arrowhead, red, stained by TUNEL), but to epidermal aggregates (arrow, magenta, stained by anti-TP63) in 24hpf <italic>hai1a<sup>hi2217</sup></italic> mutants (<bold>F</bold>) but not WT (<bold>E</bold>). (<bold>G, H</bold>) Sequence chromatograms of genomic DNA from WT (upper panels) and <italic>dandruff</italic> alleles <italic>ti251</italic> (<bold>G</bold>) and <italic>t419</italic> (<bold>H</bold>) (lower panels). Altered codon is underlined in red with altered base indicated by arrow. (<bold>I</bold>) ClustalW protein alignment of the amino acid substitution in the <italic>ti251</italic> allele showing broad conservation of across vertebrates. (<bold>J, K</bold>) Selected regions of 2D gel of protein extracted from 48hpf embryos for <italic>hai1a<sup>t419</sup></italic> (<bold>J</bold>) or <italic>hai1a<sup>ti251</sup></italic> (<bold>K</bold>) in red, superimposed over WT protein samples (green in both). The shift in pI of Peroxiredoxin4 in both alleles is indicated with an arrow. (<bold>L</bold>) Box and whiskers plot of pentafluorobenzenesulfonyl fluorescein (PFBSF) fluorescent staining intensity of WT and <italic>hai1a<sup>fr26</sup></italic> mutants at 24hpf in trunk and tail. n = 9; t-test ***p&lt;0.001. (<bold>M</bold>) Lateral projected confocal views of PFBSF staining of WT (upper row) and <italic>hai1a<sup>fr26</sup></italic> (lower row) trunks and tails at 24hpf and 48hpf. Scale bars (<bold>F</bold>) = 100 µm; (<bold>M</bold>) = 50 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig1-figsupp1-v2.tif"/></fig></fig-group><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-66596-video1.mp4"><label>Video 1.</label><caption><title>Neutrophils in WT and <italic>hai1a<sup>hi2217</sup></italic> 4dpf larva.</title><p>Projected confocal timelapses of eGFP-positive neutrophils in the tail region of 4dpf <italic>Tg(mpx:eGFP)<sup>i114</sup></italic> (left) and <italic>hai1a<sup>hi2217</sup>; Tg(mpx:eGFP)<sup>i114</sup></italic> (right) larvae taken every 45 s for 45 min. Scale bar: 50 µm.</p></caption></media><media id="video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-66596-video2.mp4"><label>Video 2.</label><caption><title>Neutrophils in WT and <italic>hai1a<sup>hi2217</sup></italic> 4dpf larva before and after fin wound.</title><p>Projected confocal timelapses of eGFP-positive neutrophils in the tail region of 4dpf <italic>Tg(mpx:eGFP)<sup>i114</sup></italic> (left) and <italic>hai1a<sup>hi2217</sup>; Tg(mpx:eGFP)<sup>i114</sup></italic> (right) larvae taken every 50 s for 250 min with the tail fin cut at 50 min. GFP is overlaid on DIC (Differential Interference Contrast) channel. Scale bar: 50 µm.</p></caption></media><p>To identify the neutrophil activator in <italic>hai1a</italic>, we employed an unbiased approach using 2D gel proteomics to compare the wild-type proteome with that of strong <italic>hai1a</italic> alleles. The <italic>dandruff (ddf)</italic> mutant has many phenotypic similarities to the strong <italic>hai1a<sup>fr26</sup></italic> allele (<xref ref-type="bibr" rid="bib67">van Eeden et al., 1996</xref>). Crosses between <italic>ddf<sup>ti251</sup></italic> or <italic>ddf<sup>t419</sup></italic> and <italic>hai1a<sup>hi2217</sup></italic> failed to complement, and sequencing of <italic>hai1a</italic> cDNA from both <italic>ddf</italic> alleles identified a nonsense mutation in the <italic>ddf<sup>t419</sup></italic> allele (c.771T&gt;G; p.Tyr257Ter) and a missense mutation of a highly conserved amino acid in the <italic>ddf<sup>ti251</sup></italic> allele (c.749G&gt;A; p.Gly250Asp) (<xref ref-type="fig" rid="fig1">Figure 1F</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G–I</xref>). We used both alleles for comparative 2D protein gel analysis at 24hpf and 48hpf. Rather than finding proteins with altered molecular weight, Peroxiredoxin4 (Prdx4) was identified as having a higher pI in both <italic>hai1a<sup>t419</sup></italic> and <italic>hai1a<sup>ti251</sup></italic> mutants at 24hpf and 48hpf, indicative of a change in oxidation state (<xref ref-type="fig" rid="fig1">Figure 1G</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1J, K</xref>). Peroxiredoxins are hydrogen peroxide scavengers, and its altered oxidation state suggested that <italic>hai1a</italic> has higher H<sub>2</sub>O<sub>2</sub> levels, a known activator of inflammation in larval zebrafish (<xref ref-type="bibr" rid="bib40">Niethammer et al., 2009</xref>). Pentafluorobenzenesulfonyl fluorescein (PFBSF) staining <xref ref-type="bibr" rid="bib33">Maeda et al., 2004</xref> demonstrated significantly higher levels of H<sub>2</sub>O<sub>2</sub> in the trunk and tails of <italic>hai1a</italic> mutants at 24hpf and 48hpf (<xref ref-type="fig" rid="fig1">Figure 1H–J</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1L, M</xref>). This increase in H<sub>2</sub>O<sub>2</sub> in <italic>hai1a</italic> was observed as early as 16hpf, and thus preceded presentation of <italic>hai1a</italic> phenotypes (<xref ref-type="fig" rid="fig1">Figure 1K, L</xref>).</p><p>To demonstrate that, as with other phenotypes, the H<sub>2</sub>O<sub>2</sub> increase in <italic>hai1a</italic> was due to unrestrained activity of Matriptase1a, we used a <italic>matriptase1a</italic> mutant allele, <italic>st14a<sup>sq10</sup></italic>, which prematurely terminates the protein at 156 amino acids (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–C</xref>; <xref ref-type="bibr" rid="bib30">Lin et al., 2019</xref>). Zygotic <italic>st14a</italic> mutants showed no overt phenotype; however, maternal zygotic mutants lacked ear otoliths (<xref ref-type="fig" rid="fig2">Figure 2B, C</xref>). As expected, when crossed into the <italic>hai1a</italic> background, embryos lacking otoliths (<italic>st14a<sup>sq10</sup>; hai1a<sup>hi2217</sup></italic> double mutants) never displayed the <italic>hai1a</italic> epidermal and neutrophil phenotypes (<xref ref-type="fig" rid="fig2">Figure 2D–F</xref>; <xref ref-type="table" rid="table1">Table 1</xref>). Double mutants also had significantly reduced H<sub>2</sub>O<sub>2</sub> levels (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). To determine if reduced H<sub>2</sub>O<sub>2</sub> could account for the rescue of <italic>hai1a</italic> phenotypes by <italic>st14a</italic> mutation, we used genetic and pharmacological inhibition of the main enzyme responsible for generating H<sub>2</sub>O<sub>2</sub> in zebrafish, Duox. A morpholino directed against <italic>duox</italic> successfully reduced H<sub>2</sub>O<sub>2</sub> levels (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>) and neutrophil inflammation in <italic>hai1a</italic> mutants but did not rescue the epithelial defects (<xref ref-type="fig" rid="fig2">Figure 2F, G</xref>). Treatment with a known Duox inhibitor, diphenyleneiodonium (DPI), also resulted in amelioration of neutrophil inflammation, but not epithelial aggregates, in <italic>hai1a</italic> mutants (<xref ref-type="fig" rid="fig2">Figure 2G</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). We conclude that Matriptase1 activity leads to excess H<sub>2</sub>O<sub>2</sub> in <italic>hai1a</italic> mutants, which partially accounts for the neutrophil inflammation, but not epidermal defects.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Loss of Matriptase1a or Duox1 reduces H<sub>2</sub>O<sub>2</sub> and neutrophils in <italic>hai1a</italic> mutants.</title><p>(<bold>A</bold>) Schematic of the Matriptase1a protein with domains given and transmembrane domain as grey line. Location and nature of the <italic>sq10</italic> allele given by red arrow. (<bold>B, C</bold>) Lateral DIC (Differential Interference Contrast) images of <italic>st14a<sup>+/sq10</sup></italic> (<bold>B</bold>) and MZ <italic>st14a<sup>sq10</sup></italic> (<bold>C</bold>) otic vesicles at 24hpf showing absence of otoliths (arrowheads in <bold>B</bold>) in the maternal zygotic <italic>st14a</italic> mutants. (<bold>D, E</bold>) Lateral DIC images of <italic>hai1a<sup>hi2217</sup></italic> single mutant (<bold>D</bold>) and <italic>st14a<sup>sq10</sup>; hai1a<sup>h12217</sup></italic> double mutant (<bold>E</bold>) at 48hpf highlighting rescue of epidermal aggregates and fin morphology (arrowheads) in the double mutants. (<bold>F</bold>) Projected confocal images of pentafluorobenzenesulfonyl fluorescein (PFBSF) staining at 24hpf (left column), TP63 (magenta), and eGFP (green) antibody staining at 48hpf (middle column) with DIC imaging (right column) for <italic>hai1a<sup>hi2217</sup></italic> single mutants (top row), <italic>st14a<sup>sq10</sup>; hai1a<sup>hi2217</sup></italic> double mutants (middle row), and <italic>hai1a<sup>hi2217</sup></italic> mutants injected with 0.4 mM, <italic>duox</italic> MO + 0.2 mM <italic>tp53</italic> morpholino (bottom row). Individuals for middle and right columns were hemizygous for the <italic>Tg(mpx:eGFP)<sup>i114</sup></italic> transgene. (<bold>G</bold>) Counts of eGFP-positive neutrophils on the fins of <italic>hai1a<sup>hi2217</sup>; Tg(mpx:eGFP)<sup>i114</sup></italic> or <italic>Tg(mpx:eGFP)<sup>i114</sup></italic>, and either uninjected, injected with morpholino against <italic>duox</italic> (left side of graph), treated with 0.5% DMSO (Dimethyl sulfoxide) or 40 µM diphenyleneiodonium (DPI) (right side of graph). n = 10; t-test; ***p&lt;0.001; *p&lt;0.05. Scale bars: (<bold>C</bold>) = 20 µm; (<bold>E</bold>, <bold>F</bold>) = 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Generation of <italic>st14a</italic> mutant and Duox inhibition reduces hydrogen peroxide and neutrophils in <italic>hai1a</italic> mutants.</title><p>(<bold>A</bold>, <bold>B</bold>) Sequence chromatograms of part of exon 6 of the zebrafish <italic>st14a</italic> gene from WT (<bold>A</bold>) and the <italic>st14a<sup>sq10</sup></italic> allele showing the 5 bp insertion highlighted by red bar. (<bold>C</bold>) Effect of the 5 bp insertion (red) in the <italic>sq10</italic> allele leads to alteration of reading frame, eight aberrant amino acids followed by a termination codon (red lettering). The codon altered to nonsense codon is underlined in both WT and mutant sequences. (<bold>D</bold>) Box and whiskers plot of pentafluorobenzenesulfonyl fluorescein (PFBSF) fluorescent staining intensity of 24hpf WT, <italic>hai1a<sup>hi2217</sup></italic> mutants, <italic>hai1a<sup>h12217</sup>; st14a<sup>sq10</sup></italic> double mutants, and <italic>hai1a<sup>hi2217</sup></italic> injected with <italic>duox</italic> MO. n = 8; ANOVA with Bonferroni post-test ***p&lt;0.001, **p&lt;0.01. (<bold>E</bold>) TP63 (magenta) and eGFP (green) antibody staining (left column) with DIC imaging (right column) for 48hpf <italic>hai1a<sup>hi2217</sup>; Tg(mpx:eGFP)<sup>i114</sup></italic> mutants either untreated (top row) or treated with 40 µM diphenyleneiodonium (DPI) (bottom row). Scale bar: (<bold>D</bold>) = 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig2-figsupp1-v2.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Prevalence of otolith and epithelial phenotypes in <italic>hai1a</italic> and <italic>st14a</italic> double mutants: p&lt;0.0001 (Chi-squared test).</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4"><italic>hai1a<sup>+/hi2217</sup>; st14a<sup>+/sq10</sup></italic> ♂ ×<italic> hai1a<sup>hi2217/hi2217</sup>; st14a<sup>sq10/sq10</sup></italic> ♀</th></tr></thead><tbody><tr><td><bold>Observed (<italic>expected</italic>)</bold></td><td><bold>WT epidermis</bold></td><td valign="top"><bold><italic>hai1a</italic> epidermis</bold></td><td valign="top"><bold>Total</bold></td></tr><tr><td>Wild-type otoliths</td><td>72 (<italic>65</italic>)</td><td>60 (<italic>65</italic>)</td><td valign="top">132 (<italic>130</italic>)</td></tr><tr><td>No otoliths</td><td>128 (65)</td><td>0 (65)</td><td valign="top">128 (<italic>130</italic>)</td></tr><tr><td>Total</td><td>200 (<italic>130</italic>)</td><td>60 (<italic>130</italic>)</td><td valign="top">260</td></tr></tbody></table></table-wrap><p>Duox is regulated by calcium through its EF-Hand domains, and calcium flashes are known to generate H<sub>2</sub>O<sub>2</sub> in epidermal wounds in <italic>Drosophila</italic> (<xref ref-type="bibr" rid="bib42">Razzell et al., 2013</xref>). We injected <italic>hai1a<sup>fr26</sup></italic> with RNA encoding the calcium reporter <italic>GCaMP6s</italic>. Timelapse imaging at 24hpf indicated that <italic>hai1a</italic> mutants had significantly more calcium flashes in both the trunk and tail (<xref ref-type="fig" rid="fig3">Figure 3A, B, E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A, B</xref>, <xref ref-type="video" rid="video3">Video 3</xref>). Increased intracellular calcium dynamics was observable as early as 16hpf, concomitant with increased H<sub>2</sub>O<sub>2</sub>, but prior to onset of <italic>hai1a</italic> phenotypes (<xref ref-type="fig" rid="fig3">Figure 3G, H</xref>, <xref ref-type="video" rid="video4">Video 4</xref>). Release of calcium from intracellular stores is regulated by IP<sub>3</sub> receptors located on the endoplasmic reticulum. The frequency and number of calcium flashes in the trunk and tail of <italic>hai1a</italic> mutants are reduced by treatment with the IP<sub>3</sub>R inhibitor, 2-APB compared to control (<xref ref-type="fig" rid="fig3">Figure 3C, D, F</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C, D</xref>, <xref ref-type="video" rid="video5">Video 5</xref>). Reducing calcium flashes in <italic>hai1a</italic> mutant embryos with 2-APB also significantly reduced H<sub>2</sub>O<sub>2</sub> levels (<xref ref-type="fig" rid="fig3">Figure 3I, J</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>) and partially reduced inflammation; however, the epidermal defects were not noticeably rescued (imaged by DIC (Differential Interference Contrast) or labelled with the TP63 antibody) (<xref ref-type="fig" rid="fig3">Figure 3I–K</xref>). We observed similar reduction in neutrophil inflammation, but not rescue of epidermal defects, in <italic>hai1a</italic> mutants treated with thapsigargin, which inhibits the replenishment of ER calcium stores by SERCA (<xref ref-type="fig" rid="fig3">Figure 3K</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F, G</xref>). This suggests, in <italic>hai1a</italic> mutants, that IP<sub>3</sub>R-dependent calcium flashes activate Duox, flooding the epidermis with H<sub>2</sub>O<sub>2</sub> and leading to inflammation.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Calcium dynamics in <italic>hai1a</italic> mutants regulate H<sub>2</sub>O<sub>2</sub> and inflammation.</title><p>(<bold>A–D</bold>) Projected confocal images of eGFP in the tail of WT (<bold>A</bold>) or <italic>hai1a<sup>fr26</sup></italic>; (<bold>B–D</bold>) injected with <italic>GCaMP6s</italic> RNA, imaged at 24hpf, indicating calcium dynamics. Embryos are either untreated (<bold>A, B</bold>), treated with DMSO (<bold>C</bold>), or with 2.5 µM 2-APB (<bold>D</bold>). Images are temporal projections of timelapse movies taken at maximum speed intervals (2 min) and projected by time. (<bold>E, F</bold>) Graphs comparing eGFP intensities from <italic>GCaMP6s</italic> RNA timelapses in trunk and tail between 24hpf WT and <italic>hai1a<sup>fr26</sup></italic> (<bold>E</bold>) and between <italic>hai1a<sup>fr26</sup></italic> treated with DMSO and 2.5 µM 2-APB (<bold>F</bold>). n = 10; t-test; *p&lt;0.05, ***p&lt;0.001. (<bold>G, H</bold>) Projected light-sheet images of <italic>Tg(actb2:GCaMP6s, myl7:mCherry)<sup>lkc2</sup></italic> embryos indicating calcium dynamics at 16hpf of sibling (<bold>G</bold>) or <italic>hai1a<sup>hi2217</sup></italic> (<bold>H</bold>). Images are temporal projections of timelapse movies taken at 45 s intervals and projected by time. (<bold>I, J</bold>) Pentafluorobenzenesulfonyl fluorescein (PFBSF) staining at 24hpf (left column), TP63 (magenta), and eGFP (green) antibody staining at 48hpf (middle column) with DIC imaging (right column) for <italic>hai1a<sup>hi2217/ti251</sup></italic> mutants (<bold>J</bold>), <italic>or hai1a<sup>hi2217/ti247</sup></italic> mutants treated with 2.5 µM 2-APB (<bold>I</bold>). Individuals for middle and right columns were hemizygous for the <italic>Tg(mpx:eGFP)<sup>i114</sup></italic> transgene. (<bold>K</bold>) Counts of eGFP-positive neutrophils in the fins at 48hpf of <italic>Tg(mpx:eGFP)<sup>i114</sup></italic>, or <italic>hai1a<sup>hi2217</sup>; Tg(mpx:eGFP)<sup>i114</sup></italic> treated with 0.5% DMSO, 2.5 µM 2-APB, or 6.5 µM thapsigargin. n = 20; t-test; ***p&lt;0.001. Scale bars (<bold>A</bold>–<bold>D</bold>) = 50 µm; (<sc><bold>G</bold></sc>, <bold>I</bold>, <bold>J</bold>) = 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Thapsigargin and 2-APB reduce neutrophil inflammation but not epidermal defects in <italic>hai1a</italic> mutants.</title><p>(<bold>A–D</bold>) Projected confocal images of eGFP in the trunk of WT (<bold>A</bold>) or <italic>hai1a<sup>fr26</sup></italic>; (<bold>B–D</bold>) injected with <italic>GCaMP6s</italic> RNA, imaged at 24hpf, indicating calcium dynamics. Embryos are either untreated (<bold>A, B</bold>), treated with DMSO (<bold>C</bold>), or with 2.5 µM 2-APB (<bold>D</bold>). Images are temporal projections of timelapse movies taken at maximum speed intervals (3 min) and projected by time. (<bold>E</bold>) Plot of pentafluorobenzenesulfonyl fluorescein (PFBSF) fluorescent staining intensity of <italic>hai1a<sup>fr26</sup></italic> mutants at 24hpf in trunk and tail, either untreated or treated with 2-APB. n = 14; ANOVA with Bonferroni post-test ***p&lt;0.001, **p&lt;0.01. (<bold>F, G</bold>) Projected confocal images of tail fins of 48hpf larvae immunostained with TP63 (magenta) and eGFP (green) (left column) with DIC imaging (right column). Larvae were both hemizygous for <italic>Tg(mpx:eGFP)<sup>i114</sup></italic> transgene and were treated with 6.5 µM thapsigargin. Genotypes are <italic>hai1a<sup>+/hi2217</sup></italic> sibling (<bold>F</bold>) and <italic>hai1a<sup>hi2217</sup></italic> mutant (<bold>G</bold>). Rescue of neutrophil inflammation, but not epidermal defect, is apparent in treated <italic>hai1a</italic> mutant. Scale bars: (<bold>A</bold>) = 50 µm; (<bold>G</bold>) = 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig3-figsupp1-v2.tif"/></fig></fig-group><media id="video3" mime-subtype="mp4" mimetype="video" xlink:href="elife-66596-video3.mp4"><label>Video 3.</label><caption><title>Calcium dynamics in WT and <italic>hai1a<sup>fr26</sup></italic> embryos at 24hpf.</title><p>Projected confocal timelapses of eGFP in the trunks (left side) and tails (right side) of a 24hpf WT (top row) and <italic>hai1a<sup>fr26</sup></italic> (bottom row) embryos injected with <italic>GCaMP6s</italic> RNA, indicating calcium dynamics. Scale bar: 50 µm.</p></caption></media><media id="video4" mime-subtype="mp4" mimetype="video" xlink:href="elife-66596-video4.mp4"><label>Video 4.</label><caption><title>Calcium dynamics in WT and <italic>hai1a<sup>hi2217</sup></italic> embryos at 16hpf.</title><p>Projected light-sheet timelapses of eGFP in WT (left side) and <italic>hai1a<sup>hi2217</sup></italic> (right side) embryos at 16hpf. Both embryos carried the <italic>Tg(actb2:GCaMP6s, myl7:mCherry)<sup>lkc2</sup></italic> transgene reporting calcium dynamics, which were higher in the <italic>hai1a</italic> mutant, particularly over the yolk. Images were taken every 45 s for 19 min. Scale bar: 50 µm.</p></caption></media><media id="video5" mime-subtype="mp4" mimetype="video" xlink:href="elife-66596-video5.mp4"><label>Video 5.</label><caption><title>Calcium dynamics in DMSO and 2-APB-treated <italic>hai1a<sup>fr26</sup></italic> embryos at 24hpf.</title><p>Projected confocal timelapses of eGFP signal in the trunks (left side) and tails (right side) of 24hpf <italic>hai1a<sup>fr26</sup></italic> embryos injected with <italic>GCaMP6s</italic> RNA and treated with 0.03% DMSO (top row) and 2.5 µM 2-APB (bottom row), indicating reduced calcium dynamics following 2-APB treatment. Scale bar: 50 µm.</p></caption></media></sec><sec id="s2-2"><title>Hydrogen peroxide elevates NfkB signalling in <italic>hai1a</italic> mutants</title><p>Increased Matriptase, Par2 activity, or hydrogen peroxide levels are known to activate NfkB signalling (<xref ref-type="bibr" rid="bib25">Kanke et al., 2001</xref>; <xref ref-type="bibr" rid="bib48">Sales et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Schreck et al., 1991</xref>). We crossed the <italic>hai1a<sup>fr26</sup></italic> allele to the NfkB sensor transgenic line <italic>Tg(6xHsa.NFKB:EGFP)<sup>nc1</sup></italic>. In WT embryos, NfkB signalling was mostly restricted to neuromasts at 48hpf, whilst in <italic>hai1a</italic> mutants we observed an increase in fluorescence at 24hpf and a strong increase at 48hpf. Fluorescence at both timepoints was noted in epidermal aggregates and fin folds, locations of strong inflammation (<xref ref-type="fig" rid="fig4">Figure 4A, B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A, B</xref>). This increase in signalling in 48hpf <italic>hai1a</italic> mutant embryos was confirmed by qRT-PCR of the NfkB target gene, <italic>nfkbiaa</italic> (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Unlike calcium and H<sub>2</sub>O<sub>2</sub>, NfkB signalling is not present at early stages prior to phenotype (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C, D</xref>). To determine the extent that NfkB signalling accounts for the <italic>hai1a</italic> phenotypes, we generated a mutant in the <italic>ikbkg</italic> (=<italic>ikkg</italic> or <italic>nemo</italic>) gene, which encodes a scaffold protein required for activating the NfkB pathway (<xref ref-type="bibr" rid="bib47">Rothwarf et al., 1998</xref>) (<italic>ikbkg<sup>sq304</sup></italic> Gly80ValfsTer11; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). Crossing this mutant to <italic>hai1a<sup>hi2217</sup></italic> on the <italic>Tg(mpx:eGFP)<sup>i114</sup></italic> background realised a very strong rescue of neutrophil inflammation at 48hpf, but no improvement of <italic>hai1a</italic> epidermal defects (<xref ref-type="fig" rid="fig4">Figure 4D–I</xref>). To demonstrate that this increase in NfkB signalling was dependent on H<sub>2</sub>O<sub>2</sub>, we injected <italic>hai1a<sup>hi2217</sup>; Tg(6xHsa.NFKB:EGFP)<sup>nc1</sup></italic> embryos with <italic>duox</italic> MO. We noted a strong reduction in NfkB pathway activation compared to uninjected <italic>hai1a<sup>hi2217</sup></italic> mutant controls (<xref ref-type="fig" rid="fig4">Figure 4J, K</xref>). Conversely, genetic ablation of NfkB signalling, through use of the <italic>ikbkg</italic> mutant, did not reduce H<sub>2</sub>O<sub>2</sub> levels in <italic>hai1a</italic> mutants (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F, G</xref>). Similarly, we tested if reduction of calcium flashes could also reduce NfkB signalling in <italic>hai1a</italic> mutants using 2-APB but noticed only a slight reduction (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1H, I</xref>). We propose that upon loss of Hai1a, IP<sub>3</sub>R-mediated release of calcium activates Duox to increase H<sub>2</sub>O<sub>2</sub>. This acts upstream of NfkB pathway activation, which occurs at later stages, and is necessary for the inflammation phenotype.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>NfkB signalling is elevated in <italic>hai1a</italic> mutants and is necessary for neutrophil inflammation.</title><p>(<bold>A, B</bold>) Lateral confocal projections of <italic>Tg(6xHsa.NFKB:EGFP)<sup>nc1</sup></italic> embryos reporting NfkB signalling levels at 48hpf for WT (<bold>A</bold>) and <italic>hai1a<sup>fr26</sup></italic> (<bold>B</bold>). (<bold>C</bold>) qPCR of cDNA levels of NfkB target gene <italic>nfkbiaa</italic> in <italic>hai1a<sup>fr26</sup></italic> vs. sibs at 48hpf. n = 3, 200 embryos pooled in each, t-test *p&lt;0.05. (<bold>D–E′</bold>) Projected confocal images of the tail fins of 48hpf <italic>Tg(mpx:eGFP)<sup>i114</sup>; hai1a<sup>hi2217</sup></italic> embryos, immunostained for TP63 (magenta) and eGFP (green) (<bold>D, E</bold>) with corresponding DIC image (<bold>D′, E′</bold>). Embryos were either mutant for <italic>ikbkg (ikbkg<sup>sq304</sup></italic>, <bold>E–E′</bold>) or heterozygous (<italic>ikbkg<sup>+/sq304</sup></italic>; <bold>D–D′</bold>). (<bold>F</bold>) Counts of eGFP-positive neutrophils in the fins at 48hpf of <italic>hai1a<sup>hi2217</sup>; ikbkg<sup>+/sq304</sup></italic> and <italic>hai1a<sup>hi2217</sup>; ikbkg<sup>sq304</sup></italic>. Embryos were hemizygous for <italic>Tg(mpx:eGFP)<sup>i114</sup></italic>. n = 9; t-test; ***p&lt;0.001. (<bold>G–I</bold>) Lateral DIC images of the trunk of <italic>hai1a<sup>+/hi2217</sup>; ikbkg<sup>+/sq304</sup></italic> (<bold>G</bold>), <italic>hai1a<sup>hi2217</sup>; ikbkg<sup>+/sq304</sup></italic> (<bold>H</bold>), and <italic>hai1a<sup>hi2217</sup>; ikbkg<sup>sq304</sup></italic> (<bold>I</bold>). Loss of IKBKG does not rescue epidermal defects of <italic>hai1a</italic> mutants (arrowheads). (<bold>J, K</bold>) Lateral confocal projections of <italic>Tg(6xHsa.NFKB:EGFP)<sup>nc1</sup></italic> embryos reporting NfkB signalling levels at 32hpf of <italic>hai1a<sup>hi2217</sup></italic> uninjected (<bold>J</bold>) or injected with <italic>duox</italic> MO (<bold>K</bold>). Loss of H<sub>2</sub>O<sub>2</sub> reduces NfkB signalling levels in <italic>hai1a</italic> mutants. Scale bars: (<bold>A</bold>, <bold>K</bold>) = 200 µm; (<bold>D</bold>′, <bold>I</bold>) = 50 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>NfkB signalling is elevated in <italic>hai1a</italic> mutants, and mutation of <italic>ikbkg</italic> rescues neutrophil inflammation.</title><p>(<bold>A–D</bold>) Lateral confocal projections of <italic>Tg(6xHsa.NFKB:EGFP)<sup>nc1</sup></italic> embryos reporting NfkB signalling levels of <italic>hai1a<sup>fr26</sup></italic> at 24hpf (<bold>B</bold>), <italic>hai1a<sup>hi2217</sup></italic> at 15hpf, and siblings at 24hpf (<bold>A</bold>) and 15hpf (<bold>C</bold>). The increase in NfkB reporter signal occurs after overt phenotype onset. (<bold>E</bold>) Nature of the <italic>ikbkg<sup>sq304</sup></italic> mutant allele showing TALEN site location within the intron-exon structure of the gene (coding and non-coding exons depicted as filled and open boxes, respectively). Sequence of part of exon 3 shown below with the TALEN binding site in red. The 14 bp deletion in the <italic>ikbkg<sup>sq304</sup></italic> allele is indicated under the WT sequence as dashes. This leads to a frameshift changing codon 80 from GGC (Gly) to GGT (Val), then nine aberrant amino acids followed by a stop codon. (<bold>F, G</bold>) Lateral widefield fluorescent images of <italic>hai1a<sup>hi2217</sup>; ikbkg<sup>+/sq304</sup></italic> (<bold>F</bold>) and <italic>hai1a<sup>hi2217</sup>; ikbkg<sup>sq304</sup></italic> (<bold>G</bold>) embryos at 24hpf stained with pentafluorobenzenesulfonyl fluorescein (PFBSF) showing no loss of H<sub>2</sub>O<sub>2</sub> in <italic>hai1a</italic> mutants upon mutation of <italic>ikbkg</italic>. (<bold>H, I</bold>) Lateral confocal projections of 48hpf <italic>hai1a<sup>fr26</sup>; Tg(6xHsa.NFKB:EGFP)<sup>nc1</sup></italic> embryos, treated with DMSO (<bold>H</bold>) or with 2.5 µM 2-APB (<bold>I</bold>). Scale bars: (<bold>A</bold>, <bold>H</bold>) = 200 µm; (<bold>C</bold>) = 100 µm; (<bold>F</bold>) = 50 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Both inflammation and epidermal aggregates of <italic>hai1a</italic> mutants are resolved by Gq inhibition</title><p>IP<sub>3</sub> is generated from cleavage of PIP<sub>2</sub> by Phospholipase C. The sensitivity of the <italic>hai1a</italic> mutants to 2-APB implies that IP<sub>3</sub> levels are increased and therefore there may be an increase in Phospholipase C activity. Numerous attempts to inhibit PLC in <italic>hai1a</italic> mutants failed, and we were unable to find a dosage window that rescued without gross embryo deformity. Hence, we tested rescue of <italic>hai1a</italic> mutants with YM-254890, an inhibitor of the heterotrimeric G protein alpha subunit, Gq, which directly activates PLC isoforms. We found that not only did this significantly reduce neutrophil inflammation (<xref ref-type="fig" rid="fig5">Figure 5D, F</xref>), but surprisingly, it also significantly rescued the epidermal defects in <italic>hai1a</italic> mutants, with a significant reduction in TP63-positive epidermal aggregates in the trunk and improved tail fin fold integrity at 48hpf (<xref ref-type="fig" rid="fig5">Figure 5A–E</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Gq inhibition rescues both epidermal and inflammation phenotypes of <italic>hai1a</italic> mutants.</title><p>(<bold>A–D</bold>) Lateral images of ventral trunk and tail at 48hpf for WT (left panels), <italic>hai1a<sup>hi2217</sup></italic> treated with 0.5% DMSO (middle panels), and <italic>hai1a<sup>hi2217</sup></italic> treated with 32 µM YM-254890 (right panels). DIC micrographs are shown in (<bold>A</bold>, <bold>B</bold>), whilst projected confocal images are shown in (<bold>C</bold>, <bold>D</bold>), where embryos are immunostained for TP63 (<bold>C</bold>, <bold>D</bold>; magenta) and eGFP (<bold>D</bold>; green). Embryos in (<bold>D</bold>) are hemizygous for <italic>Tg(mpx:eGFP)<sup>i114</sup></italic>. Arrowheads indicate region of aggregate formation lost upon treatment with Gq inhibitor YM-254890. (<bold>E</bold>) Pie charts showing proportion of embryos with no (WT; white), mild (grey) or severe (black) <italic>hai1a</italic> mutant epidermal phenotypes. Embryos were derived from <italic>hai1a<sup>hi2217/hi2217</sup></italic> × <italic>hai1a<sup>+/hi2217</sup></italic> crosses and assayed at 48hpf. Clutches treated with 0.5% DMSO (upper pie chart) were compared to those treated with 32 µM YM-254890 (lower pie chart) by Chi-squared analysis. ***p&lt;0.001; n = 72. (<bold>F</bold>) Graph of counts of eGFP-positive neutrophils in the fins at 48hpf of <italic>Tg(mpx:eGFP)<sup>i114</sup></italic>, or <italic>hai1a<sup>hi2217</sup>; Tg(mpx:eGFP)<sup>i114</sup></italic> treated with 0.5% DMSO, or 32 µM YM-254890. n = 6; Mann–Whitney test; **p&lt;0.01. Scale bars: (<bold>A</bold>–<bold>D</bold>) = 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig5-v2.tif"/></fig></sec><sec id="s2-4"><title>PMA treatment phenocopies the <italic>hai1a</italic> mutant</title><p>As IP<sub>3</sub>R inhibition only blocks inflammation in <italic>hai1a</italic> mutants, but an inhibitor of a PLC activator (Gq) additionally reduces the epidermal defects, we considered that diacyl glycerol (DAG) might contribute to the epidermal defects as the second product of PIP<sub>2</sub> cleavage (along with IP<sub>3</sub>). Indeed, treating WT embryos from 15hpf to 24hpf with 125 ng/ml phorbol 12-myristate 13-acetate (PMA), a DAG analogue, resulted in embryos with striking similarities to strong <italic>hai1a</italic> mutants, including a thin or absent yolk sac extension, lack of head straightening, lack of lifting the head off the yolk, and multiple epidermal aggregates on the skin (<xref ref-type="fig" rid="fig6">Figure 6A–C</xref>). These aggregates were due, at least partially, to displacement of basal keratinocytes as shown by TP63 staining where the basal keratinocyte nuclei lost their uniform distribution (<xref ref-type="fig" rid="fig6">Figure 6D, E</xref>). Treatment from 24hpf to 48hpf with 125 ng/ml PMA led to a fin defect similar to the dysmorphic <italic>hai1a</italic> mutant fin (<xref ref-type="fig" rid="fig6">Figure 6F, G</xref>). It has been shown that the basal keratinocytes in <italic>hai1a</italic> lose their epithelial nature and adopt a partially migratory phenotype (<xref ref-type="bibr" rid="bib8">Carney et al., 2007</xref>; <xref ref-type="video" rid="video6">Video 6</xref>). We treated <italic>Tg(krtt1c19e:lyn-tdtomato)<sup>sq16</sup></italic> larvae (<xref ref-type="bibr" rid="bib29">Lee et al., 2014</xref>) with 37.5 ng/ml PMA for 12 hr and imaged the basal epidermis at 3dpf by light-sheet timelapse. Whilst the DMSO-treated transgenic larvae had very stable keratinocyte membranes and shape, PMA treatment led to a less stable cell membrane topology and dynamic cell shape, similar to <italic>hai1a</italic> mutants (<xref ref-type="fig" rid="fig6">Figure 6H</xref>, <xref ref-type="video" rid="video7">Videos 7</xref> and <xref ref-type="video" rid="video8">8</xref>). Kymographs taken from <xref ref-type="video" rid="video7">Video 7</xref> highlighted both the more labile and weaker cell membrane staining following PMA treatment (<xref ref-type="fig" rid="fig6">Figure 6I</xref>). The potency of PMA was dependant on region and reduced with age.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Phorbol 12-myristate 13-acetate (PMA) induces epidermal aggregates, motility, H<sub>2</sub>O<sub>2</sub>, NfkB, and inflammation.</title><p>(<bold>A, B</bold>) Lateral micrographs of embryos treated with DMSO (<bold>A</bold>) or 125 ng/ml PMA (<bold>B, C</bold>) showing generation of epidermal aggregates (arrowheads). (<bold>D, E</bold>) Projected confocal images of the trunk of 24hpf WT embryos treated with 0.1% DMSO (<bold>D</bold>) or 125 ng/ml PMA (<bold>E</bold>) and immunostained for TP63 (magenta), showing aggregation of TP63-positive cells. (<bold>F, G</bold>) Projected confocal images superimposed on DIC image of the tail of 48hpf <italic>Tg(mpx:eGFP)<sup>i114</sup></italic> embryos treated with 0.1% DMSO (<bold>F</bold>) or 125 ng/ml PMA (<bold>G</bold>) showing fin defect and activation of eGFP-positive neutrophils (green, <bold>G</bold>). (<bold>H, I</bold>) Single timepoint images at t = 0 (top panels, <bold>H</bold>) and t = 1800 s (lower panels, <bold>H</bold>) and kymographs (<bold>I</bold>) derived from light-sheet movies (<xref ref-type="video" rid="video7">Video 7</xref>) of the epidermis of 3dpf <italic>Tg(krtt1c19e:lyn-tdtomato)<sup>sq16</sup></italic> larvae treated with 0.1% DMSO (left panels) or 37.5 ng/ml PMA (right panels) showing the lack of membrane stability following PMA treatment. (<bold>J–K′</bold>) Single frames (<bold>J, K</bold>) and tracks of eGFP- positive neutrophils (<bold>J′, K′</bold>) from light-sheet (<xref ref-type="video" rid="video8">Video 8</xref>) showing neutrophils labelled by eGFP and basal keratinocyte cell membranes labelled by lyn-tdTomato in the trunk of a 3dpf <italic>Tg(krtt1c19e:lyn-tdtomato)<sup>sq16</sup></italic> larva treated with 0.1% DMSO (<bold>J, J′</bold>) or 37.5 ng/ml PMA (<bold>K, K′</bold>) for 18 hr, and imaged every 20 s for 30 min. Track colour in (<bold>J</bold>′, <bold>K</bold>′) denotes mean velocity (dark blue 0.0 – red 0.2). (<bold>L–O</bold>) Projected lateral confocal views of pentafluorobenzenesulfonyl fluorescein (PFBSF) staining of 24hpf WT embryos treated with 0.1% DMSO (<bold>L, N</bold>) or 125 ng/ml PMA (<bold>M, O</bold>) showing elevation of H<sub>2</sub>O<sub>2</sub> in the trunk (<bold>L, M</bold>) and tail (<bold>N, O</bold>). (<bold>P, Q</bold>) Projected confocal images of eGFP in the tail at 24hpf of WT injected with <italic>GCaMP6s</italic> RNA, treated with DMSO (<bold>P</bold>), or with 125 ng/ml PMA (<bold>Q</bold>). Images are temporal projections of timelapse movies taken at maximum speed intervals (2 min) and projected by time. (<bold>R</bold>) Plot of PFBSF fluorescent staining intensity of WT embryos treated with 0.1% DMSO or 125 ng/ml PMA in the trunk and tail. n = 6; ANOVA with Bonferroni post-test **p&lt;0.01. (<bold>S</bold>) Graph comparing eGFP intensities from 24hpf <italic>GCaMP6s</italic> RNA timelapses in tail following treatment with DMSO and 125 ng/ml PMA. n = 10; t-test. (<bold>T–U</bold>) Lateral confocal projections of <italic>Tg(6xHsa.NFKB:EGFP)<sup>nc1</sup></italic> embryos reporting NfkB signalling levels at 48hpf in WT treated with DMSO (<bold>T</bold>) and WT treated with 125 ng/ml PMA (<bold>U</bold>). Scale bars: (<bold>A</bold>, <bold>B</bold>, <bold>C</bold>, <bold>F</bold>) = 100 µm; (<bold>D</bold>, <bold>J</bold>, <bold>Q</bold>) = 50 µm; (<bold>H</bold>, <bold>I</bold>) = 20 µm; (<bold>U</bold>) = 200 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig6-v2.tif"/></fig><media id="video6" mime-subtype="mp4" mimetype="video" xlink:href="elife-66596-video6.mp4"><label>Video 6.</label><caption><title>Basal keratinocyte membrane and neutrophil dynamics in 3dpf wild-type and <italic>hai1a<sup>hi2217</sup></italic> larvae carrying the <italic>Tg(krtt1c19e:lyn-tdtomato)<sup>sq16</sup></italic> and <italic>Tg(mpx:eGFP)<sup>i114</sup></italic> transgenes.</title><p>Projected light-sheet timelapses of the trunk of 3dpf WT (left) and <italic>hai1a<sup>hi2217</sup></italic> (right) larvae with neutrophils and basal keratinocyte membranes labelled by eGFP and lyn-tdTomato, respectively. Both larvae carried the <italic>Tg(krtt1c19e:lyn-tdtomato)<sup>sq16</sup>; Tg(mpx:eGFP)<sup>i114</sup></italic> transgenes. The <italic>hai1a</italic> mutants have highly dynamic neutrophils and keratinocyte membrane dynamics. Scale bar: 20 µm.</p></caption></media><media id="video7" mime-subtype="mp4" mimetype="video" xlink:href="elife-66596-video7.mp4"><label>Video 7.</label><caption><title>Basal keratinocyte membranes in DMSO and phorbol 12-myristate 13-acetate (PMA)-treated 3dpf <italic>Tg(krtt1c19e:lyn-tdtomato)<sup>sq16</sup></italic> larvae.</title><p>Zoomed projected light-sheet timelapses of basal keratinocyte membranes labelled by lyn-tdTomato in the trunk of 3dpf <italic>Tg(krtt1c19e:lyn-tdtomato)<sup>sq16</sup></italic> larvae treated with 0.1% DMSO (left) and 37.5 ng/ml PMA (middle and right) for 18 hr. Membranes are stable in DMSO-treated larvae but were dynamic in PMA-treated larvae. Images were captured every 20 s. Scale bar: 10 µm.</p></caption></media><media id="video8" mime-subtype="mp4" mimetype="video" xlink:href="elife-66596-video8.mp4"><label>Video 8.</label><caption><title>Neutrophils and basal keratinocyte membranes in DMSO and phorbol 12-myristate 13-acetate (PMA)-treated 3dpf <italic>Tg(krtt1c19e:lyn-tdtomato)<sup>sq16</sup>; Tg(mpx:eGFP)<sup>i114</sup></italic> larvae.</title><p>Lateral projection of light-sheet timelapse of neutrophils labelled by eGFP and basal keratinocyte cell membranes labelled by lyn-tdTomato in the trunks of 3dpf <italic>Tg(krtt1c19e:lyn-tdtomato)<sup>sq16</sup></italic> larva treated with 0.1% DMSO (left) and 37.5 ng/ml PMA (right) for 18 hr. PMA treatment leads to slightly dynamic cell membranes and motile neutrophils. Images were captured every 20 s for 30 min. Scale bar: 50 µm.</p></caption></media><p>Most PMA-treated <italic>Tg(mpx.eGFP)<sup>i114</sup></italic> larvae at 48hpf also had more neutrophils in the epidermis than untreated controls, which were highly migratory (<xref ref-type="fig" rid="fig6">Figure 6F–G, J–K′</xref>, <xref ref-type="video" rid="video8">Video 8</xref>). We determined H<sub>2</sub>O<sub>2</sub> levels in PMA-treated embryos using PFBSF staining and found that it was significantly increased in both trunk and tail at 24hpf (<xref ref-type="fig" rid="fig6">Figure 6L–O, R</xref>). In contrast, when we treated <italic>GCaMP6s</italic> RNA-injected embryos with PMA, we failed to see an increase in calcium flashes, as seen in <italic>hai1a</italic> (<xref ref-type="fig" rid="fig6">Figure 6P, Q, S</xref>). To see if the heightened H<sub>2</sub>O<sub>2</sub> and inflammation was also correlated with increased NfkB signalling, we treated <italic>Tg(6xHsa.NFKB:EGFP)<sup>nc1</sup></italic> embryos with 125 ng/ml PMA. There was a robust increase in fluorescence, indicating that PMA activates the NfkB pathway (<xref ref-type="fig" rid="fig6">Figure 6T, U</xref>).</p><p>The phenocopy and the rescue of <italic>hai1a</italic> by PMA and Gq inhibition respectively imply that DAG is elevated in <italic>hai1a</italic> mutants. Elevated cellular DAG leads to relocalisation of Protein Kinase C isoforms to the plasma and nuclear lipid membranes where they bind DAG and become activated. Using a GFP-tagged PKCδ fusion protein (<xref ref-type="bibr" rid="bib58">Sivak et al., 2005</xref>), we showed that in the WT embryo there was largely diffuse cytoplasmic PKCδ-GFP signal, however, it translocated to plasma and nuclear membranes in <italic>hai1a</italic> mutants, indicating increased levels of DAG (<xref ref-type="fig" rid="fig7">Figure 7A, B</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A, B</xref>). This is indeed relevant to the epidermal defects, as treatment of <italic>hai1a<sup>hi2217</sup></italic> embryos with the PKC inhibitor, GFX109203, reduced the epidermal aggregates and disruption of fin morphology as imaged by DIC or immunostaining for TP63 (<xref ref-type="fig" rid="fig7">Figure 7C–H</xref>). Neutrophil inflammation in the epidermis was somewhat reduced, but not to a significant degree (<xref ref-type="fig" rid="fig7">Figure 7E–I</xref>). Thus, these experiments strongly suggest that epithelial defects of <italic>hai1a</italic> are due to DAG generation and PKC activation.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Inhibition of PKC rescues epidermal defects of <italic>hai1a</italic>.</title><p>(<bold>A, B</bold>) Confocal images of the ventral fin of 22hpf sibling (<bold>A</bold>) or <italic>hai1a<sup>hi2217</sup></italic> (<bold>B</bold>) embryos injected with RNA encoding PKCδ-GFP. Mostly cytoplasmic distribution in sibling was relocated to cell and nuclear membranes in <italic>hai1a</italic> mutants. (<bold>C, D</bold>) Lateral brightfield images of 48hpf <italic>hai1a<sup>hi2217</sup></italic> larvae treated with 0.5% DMSO (<bold>C</bold>) or 85 µM GFX109203 (<bold>D</bold>). Epidermal aggregates and fin deterioration are rescued by the PKC inhibitor (arrowheads). (<bold>E–H</bold>) DIC (<bold>E, G</bold>) and projected confocal images (<bold>E′, G′, F, H</bold>) of <italic>hai1a<sup>hi2217</sup>; Tg(mpx:eGFP)<sup>i114</sup></italic> trunk at 24hpf (<bold>E–E′, G–G′</bold>) and tail at 48hpf (<bold>F, H</bold>), either treated with 0.5% DMSO (<bold>E–F</bold>) or 85 µM GFX109203 (<bold>G–H</bold>). Embryos are immunostained for TP63 (magenta) and eGFP (green), highlighting rescue of epidermal phenotype and partial rescue of neutrophils by GFX109203. (<bold>I</bold>) Counts of eGFP-positive neutrophils in the fins at 48hpf of <italic>Tg(mpx:eGFP)<sup>i114</sup></italic>, or <italic>hai1a<sup>hi2217</sup>; Tg(mpx:eGFP)<sup>i114</sup></italic> treated with 0.5% DMSO or 85 µM GFX109203. n = 8; ANOVA, Dunn’s multiple comparisons; **p&lt;0.01. Scale bars: (<bold>A</bold>) = 10 µm; (<bold>D</bold>) = 200 µm; (<bold>H</bold>) = 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Relocation of PKCδ-GFP to membranes in <italic>hai1a</italic> mutants.</title><p>(<bold>A, B</bold>) Projected confocal images of the tail of 22hpf sibling (<bold>A</bold>) or <italic>hai1a<sup>hi2217</sup></italic> (<bold>B</bold>) embryos injected with RNA encoding PKCδ-GFP. Mostly cytoplasmic distribution in siblings was relocated to cell and nuclear membranes in <italic>hai1a</italic> mutants, suggesting increased cellular diacyl glycerol levels. Scale bar: (<bold>A</bold>) = 10 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig7-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Elevated MAPK signalling generates epithelial defects in <italic>hai1a</italic></title><p>We next sought to determine which pathways downstream of PKC are responsible for the epidermal defects. The MAPK pathway is a major target pathway of multiple PKC isoforms, and activation of this pathway in zebrafish epidermis has previously been shown to induce papilloma formation which have very similar attributes to <italic>hai1a</italic> mutant aggregates (<xref ref-type="bibr" rid="bib11">Chou et al., 2015</xref>). Although whole embryo western analysis of <italic>hai1a</italic> mutants failed to show an overall increase in pERK (<xref ref-type="bibr" rid="bib6">Armistead et al., 2020</xref>), we performed wholemount immunofluorescent analysis in case there was only a localised effect. Indeed, we observed a significant and localised increase in cytoplasmic pERK immunoreactivity (phospho-p44/42 MAPK (Erk1/2) (Thr<sup>202</sup>/Tyr<sup>204</sup>)) in the regions of epidermal aggregate formation in <italic>hai1a</italic> mutants and in PMA-treated embryos, including under the yolk at 24hpf and in the fins at 24hpf and 48hpf (<xref ref-type="fig" rid="fig8">Figure 8A–K</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A–F</xref>). There was no increase in total ERK levels in the mutant (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1M, N</xref>). Increased pERK was seen in both the cytoplasm and nucleus of TP63-positive cells but was only increased in the nucleus of periderm cells (<xref ref-type="fig" rid="fig8">Figure 8E–E′</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1D</xref>). To establish that this is an early marker of aggregate formation, and not a sequela, we stained <italic>hai1a</italic> mutant embryos at earlier timepoints. We found that at 16hpf regions of the epidermis have pERK staining before overt aggregation formation (<xref ref-type="fig" rid="fig8">Figure 8G–H</xref>), whilst nascent aggregates also contain pERK staining which increases in number over time (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1G–L</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Elevation of pERK levels in phorbol 12-myristate 13-acetate (PMA)-treated and <italic>hai1a</italic> mutant epidermis.</title><p>(<bold>A–L</bold>) Lateral projected confocal images of trunks (<bold>A, A′, B, E, E′, F</bold>), yolk surface (<bold>G, G′, H</bold>) and tails (<bold>C, C′, D, I, I′, J</bold>) of embryos immunostained for TP63 (<bold>A</bold>′, <bold>B</bold>, <bold>C</bold>′, <bold>D</bold>, <bold>E</bold>′, <bold>F</bold>, <bold>G</bold>′, <bold>H</bold>, <bold>I</bold>′, <bold>J</bold>; magenta) and pERK (<bold>A</bold>, <bold>J</bold>; green) at 24hpf (<bold>A–F</bold>), 16hpf (<bold>G–H</bold>), and 48hpf (<bold>I–J</bold>). Both <italic>hai1a<sup>fr26</sup></italic> (<bold>A, A′, C, C′, E, E′, G, G′</bold>) and 125 ng/ml PMA-treated (<bold>I, I′</bold>) embryos show increased epidermal pERK levels compared to untreated WT (<bold>B, D, F, H, J</bold>). Elevation of epidermal pERK in <italic>hai1a<sup>fr26</sup></italic> mutants and PMA- treated embryos is seen in the trunk (<bold>A, E</bold>) and tail (<bold>C, I</bold>) as well as in epidermis over the yolk prior to overt phenotype manifestation (<bold>G</bold>). (<bold>K</bold>) Quantification of pERK immunofluorescent intensity in the tail of 24hpf <italic>hai1a<sup>fr26</sup></italic> larvae compared to siblings. n = 5; Mann–Whitney test; **p&lt;0.01. Scale bars: (<bold>B</bold>) = 100 µm; (<bold>D</bold>, <bold>H</bold>, <bold>J</bold>) = 50 µm; (<bold>F</bold>) = 20 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Elevation of pERK levels in phorbol 12-myristate 13-acetate (PMA)-treated and <italic>hai1a</italic> mutant epidermis.</title><p>(<bold>A–J</bold>) Lateral projected confocal images of ventral trunks (<bold>A–C</bold>), tails (<bold>D–F</bold>), and whole embryos (<bold>G–L</bold>) immunostained for TP63 (magenta) and pERK (green) at 24hpf (<bold>A–D, K, L</bold>), 48hpf (<bold>E, F</bold>), 16hpf (<bold>G, H</bold>), and 20hpf (<bold>I, J</bold>). Both <italic>hai1a<sup>fr26</sup></italic> (<bold>C, D, F, H, J, L</bold>) and 125 ng/ml PMA-treated (<bold>B</bold>) embryos show increased epidermal pERK levels compared to untreated WT (<bold>A, E, G, I, K</bold>). Elevation of epidermal pERK is seen in <italic>hai1a<sup>fr26</sup></italic> mutants and PMA treated embryos as well as in nascent aggregates (arrowheads, <bold>H, J</bold>). (<bold>M, N</bold>) Lateral projected confocal images of the trunks of WT (<bold>M</bold>) and <italic>hai1a<sup>fr26</sup></italic> (<bold>N</bold>) embryos immunostained with total ERK (tERK; green) and TP63 (magenta). There was no change in tERK in <italic>hai1a<sup>fr26</sup></italic> (<bold>N</bold>) compared to WT (<bold>M</bold>). Scale bars: (<bold>C</bold>, <bold>F</bold>, <bold>N</bold>) = 50 µm; (<bold>D</bold>) = 20 µm; (<bold>H</bold>, <bold>J</bold>, <bold>K</bold>, <bold>L</bold>) = 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig8-figsupp1-v2.tif"/></fig></fig-group><p>To determine if elevated pERK is causative of epidermal defects, we attempted to rescue using pERK inhibitors. Initially we used PD0325901; however, this appeared to give fin fold deformities, even in WT embryos (<xref ref-type="bibr" rid="bib4">Anastasaki et al., 2012</xref>), precluding ability to assess rescue in <italic>hai1a</italic>, although there was a noticeable reduction in epidermal aggregates forming under the yolk-sac extension (data not shown). Instead, we tried U0126 and CI-1040, other well-known pERK inhibitors (<xref ref-type="bibr" rid="bib2">Allen et al., 2003</xref>; <xref ref-type="bibr" rid="bib17">Favata et al., 1998</xref>). Both inhibitors showed a significant reduction in <italic>hai1a</italic> mutant epidermal aggregates under the yolk, and restoration of the overall and tail epithelial morphology, with embryos showing a <italic>hai1a</italic> phenotype class significantly reduced (<xref ref-type="fig" rid="fig9">Figure 9A–G</xref>, <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A–F</xref>). Similarly, the epidermal defects of the trunk, yolk, and tail following PMA treatment were also ameliorated by concomitant U0126 treatment (<xref ref-type="fig" rid="fig9">Figure 9H, I</xref>, <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1G, H</xref>). Rescue of aggregates and tail morphology following PMA treatment or in <italic>hai1a</italic> mutants could be visualised by immunolabelling TP63 in basal keratinocyte nuclei (<xref ref-type="fig" rid="fig9">Figure 9J–O</xref>, <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1I, J</xref>). Initiating U0126 treatment later at 26hpf led to only a partial rescue, indicating that the epidermal phenotypes were likely due to sustained pERK activation (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1K–M′</xref>).</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Rescue of the <italic>hai1a</italic> epidermal phenotype by pERK inhibitors.</title><p>(<bold>A–F</bold>) Lateral DIC images of 24hpf (<bold>A, B</bold>) or 48hpf (<bold>C–F</bold>) <italic>hai1a<sup>hi2217</sup></italic> embryos treated with either DMSO (<bold>A, C, E</bold>), 1.3 µM CI-1040 (<bold>B</bold>), or 100 µM U0126 (<bold>D, F</bold>) showing rescue of general morphology (<bold>B</bold>), trunk (<bold>D</bold>), and tail (<bold>F</bold>) epidermal phenotypes compared to DMSO-treated <italic>hai1a<sup>hi2217</sup></italic>. Epidermal aggregates under the yolk are reduced in the treated mutants (<bold>A</bold>–<bold>D</bold>; arrowheads). (<bold>G</bold>) Proportion of 48hpf larvae derived from <italic>hai1a<sup>+/hi2217</sup></italic> incross showing mild or severe <italic>hai1a</italic> epidermal phenotype following DMSO (upper) or U0126 (lower) treatment (Chi-squared test). (<bold>H, I</bold>) Lateral DIC images of 24hpf embryo treated with 125 ng/ml phorbol 12-myristate 13-acetate (PMA) (<bold>H</bold>) or PMA and U0126 (<bold>I</bold>). Yolk-associated epidermal aggregates are reduced. (<bold>J–M</bold>) Lateral projected confocal images of <italic>hai1a<sup>hi2217</sup>; Tg(mpx:eGFP)<sup>i114</sup></italic> trunk at 24hpf (<bold>J, K</bold>) and tail at 48hpf (<bold>L, M</bold>), either treated with 0.5% DMSO (<bold>J, L</bold>) or U0126 (<bold>K, M</bold>). Embryos are immunostained for TP63 (magenta) and eGFP (green), highlighting rescue of epidermal phenotype but no reduction of neutrophils. (<bold>N, O</bold>) Lateral projected confocal images of <italic>Tg(mpx:eGFP)<sup>i114</sup></italic> treated with PMA alone (<bold>N</bold>) or PMA with U0126 (<bold>O</bold>) and immunostained for TP63 (magenta) and eGFP (green). Fin morphology is restored but neutrophils are still present. (<bold>P</bold>) Quantification of neutrophils in the fins showing U0126 does not reduce inflammation induced by loss of <italic>hai1a</italic> or PMA treatment. n = 8; ANOVA with Bonferroni post-test; ***p&lt;0.001. (<bold>Q–X</bold>) Projected confocal images of 48hpf larval tails immunostained for β-catenin (green) and TP63 (magenta; <bold>R, T, V, X</bold>) of WT (<bold>Q, R, U, V</bold>) and <italic>hai1a<sup>hi2217</sup></italic> (<bold>S, T, W, X</bold>), either untreated (<bold>Q–T</bold>), treated with PMA (<bold>U, V</bold>) or U0126 (<bold>W, X</bold>). (<bold>Y</bold>–<bold>AA</bold>) Profile plots of fluorescence distribution across cells of WT (<bold>Y</bold>), <italic>hai1a<sup>hi2217</sup></italic> (<bold>Z</bold>), and <italic>hai1a<sup>hi2217</sup></italic> treated with U0126 (<bold>AA</bold>). X-axis represents width of the cell. β-catenin immunofluorescence intensity (Y-axis) shows majority at cell edge (demarcated in light purple) in WT and rescued <italic>hai11a</italic> mutants, but is distributed in cytoplasm in mutant. Two cells per 3–5 larvae were analysed. Scale bars: (<bold>B</bold>) = 200 µm, (<bold>F</bold>, <bold>I</bold>, <bold>K</bold>, <bold>O</bold>) = 100 µm, (<bold>V</bold>) = 20 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig9-v2.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>Rescue of the <italic>hai1a</italic> epidermal phenotype by pERK inhibitors.</title><p>(<bold>A–F</bold>) Lateral DIC images of 24hpf (<bold>A, B</bold>) or 48hpf (<bold>C–F</bold>) <italic>hai1a<sup>hi2217</sup></italic> embryos treated with either DMSO (<bold>A, C, E</bold>), U0126 (<bold>B</bold>), or CI-1040 (<bold>D, F</bold>) showing rescue of general morphology (<bold>B</bold>), trunk (<bold>D</bold>), and tail (<bold>F</bold>) epidermal phenotypes compared to DMSO-treated <italic>hai1a<sup>hi2217</sup></italic>. (<bold>G, H</bold>) Lateral DIC images of tails of 48hpf WT treated with 125 ng/ml phorbol 12-myristate 13-acetate (PMA) alone (<bold>G</bold>) or PMA and U0126 (<bold>H</bold>). (<bold>I, J</bold>) Lateral projected confocal images of trunks of 48hpf <italic>hai1a<sup>hi2217</sup></italic> embryos treated with DMSO (<bold>I</bold>) or U0126 (<bold>J</bold>) and then fluorescently immunostained for TP63. (<bold>K–M′</bold>) Lateral DIC images of the trunks (<bold>K, L, M</bold>) and tails (<bold>K′, L′, M′</bold>) of 48hpf <italic>hai1a<sup>hi2217</sup></italic> embryos either untreated (<bold>M, M′</bold>), treated with 100 µM U0126 from 16hpf to 48hpf (<bold>L, L′</bold>), or treated with U0126 from 26hpf to 48hpf (<bold>M, M′</bold>). Whilst treatment from 16hpf led to a complete rescue, initiating treatment later resulted in only partial rescue. Scale bars: (<bold>B</bold>) = 200 µm; (<bold>C</bold>, <bold>H</bold>, <bold>I</bold>, <bold>M</bold>′) = 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig9-figsupp1-v2.tif"/></fig><fig id="fig9s2" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 2.</label><caption><title>The barrier function of the <italic>hai1a</italic> epidermis is not grossly compromised.</title><p>(<bold>A–D′</bold>) Lateral confocal images of the tails (<bold>A</bold>–<sc><bold>B</bold></sc>′; <bold>D, D′</bold>) and trunk (<bold>C, C′</bold>) of 36hpf WT (<bold>A</bold>, <bold>A</bold>′; <bold>D</bold>, <bold>D</bold>′) and <italic>hai1a<sup>hi2217</sup></italic> embryos (<bold>B–C′</bold>) immersed in 2.5 mg/ml of 3–5 kDa fluorescein dextran for 30 min before brief destaining. Fluorescent images (<bold>A–D</bold>) are also shown overlaying DIC images (<bold>A′–D′</bold>). (<bold>E, F</bold>) Lateral DIC images of the tails (<bold>E, F, H</bold>) and trunk (<bold>G</bold>) of 36hpf WT (<bold>E, H</bold>) and <italic>hai1a<sup>hi2217</sup></italic> embryos (<bold>F, G</bold>) immersed in 0.075% of methylene blue for 30 min before brief destaining. Tails of WT embryos in (<bold>H</bold>) were wounded by scalpel cut before immersion. Scale bars: (<bold>D</bold>′, <bold>H</bold>) = 50 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig9-figsupp2-v2.tif"/></fig></fig-group><p>Treatment with U0126 did not significantly reduce neutrophil inflammation of <italic>hai1a</italic> mutants or PMA treatment (<xref ref-type="fig" rid="fig9">Figure 9L–P</xref>). This suggests that the inflammation phenotype is not simply a consequence of the epidermal defects. Furthermore, dye penetration assays showed that the epithelial barrier was not globally and overtly compromised in <italic>hai1a</italic>, underscoring that inflammation is not simply a consequence of epithelial defects (<xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2A–H</xref>). It has been shown that the epidermal defects in <italic>hai1a</italic> are associated with loss of E-cadherin from adherens junctions (<xref ref-type="bibr" rid="bib8">Carney et al., 2007</xref>). As there was a rescue of the epithelial phenotype following pERK inhibition, we looked at the status of the adherens junction marker β-catenin. Whilst the WT basal epidermal cells of the 48hpf tail showed strong staining at the membrane, <italic>hai1a</italic> mutants and PMA-treated embryos showed a significant loss of β-catenin at the membrane and increase in the cytoplasm (<xref ref-type="fig" rid="fig9">Figure 9Q–V, Y, Z</xref>). Treatment of <italic>hai1a</italic> mutants with U0126 restored the membrane localisation of β-catenin (<xref ref-type="fig" rid="fig9">Figure 9W, X</xref>, AA).</p></sec><sec id="s2-6"><title>Phosphorylation of cytoplasmic RSK by pERK leads to loss of E-cadherin at the <italic>hai1a</italic> keratinocyte membrane</title><p>As increased pERK appeared to contribute strongly to loss of adherens junctions and removal of E-cadherin/β-catenin from the membrane, we sought to determine how pERK signalling might affect adherens junctions. We predicted that this would occur through a cytoplasmic target of pERK as we have previously shown that there is no transcriptional downregulation of E-cadherin levels in <italic>hai1a,</italic> making a nuclear transcription factor target less likely to be relevant (<xref ref-type="bibr" rid="bib8">Carney et al., 2007</xref>). The p90RSK family of kinases represents direct cytoplasmic targets of Erk1/2 phosphorylation which regulate cell motility, and thus were good candidates for mediators disrupting cell-cell adhesion (<xref ref-type="bibr" rid="bib9">Čáslavský et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Tanimura and Takeda, 2017</xref>). We determined that at least RSK2a (=p90RSK2a, encoded by <italic>rps6ka3a</italic>) is expressed in basal keratinocytes at 24hpf (<xref ref-type="fig" rid="fig10">Figure 10A, B</xref>). To gauge if there was an alteration in phosphorylation of RSK family members in the epidermis of <italic>hai1a</italic> mutants, we used an antibody which detects a phosphorylated site of mouse p90RSK (Phospho-Thr<sup>348</sup>). This site is phosphorylated in an ERK1/2-dependent manner (<xref ref-type="bibr" rid="bib46">Romeo et al., 2012</xref>). We noticed a substantial increase in cytoplasmic signal in both <italic>hai1a</italic> mutants and PMA-treated embryos. Where p90RSK-pT<sup>348</sup> signal was largely nuclear in both basal and periderm cells in WT, it was more broadly observed in <italic>hai1a</italic> mutant fins, with an increase in the cytoplasm leading to a more uniform staining (<xref ref-type="fig" rid="fig10">Figure 10C–D′</xref>). This increase in cytoplasmic levels of p90RSK-pT<sup>348</sup> was observable at 17hpf prior to epithelial defects (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1A–C</xref>). p90RSK cytoplasmic signal was lost upon U0126 and GFX109203 treatments, showing that it was pERK and PKC dependant (<xref ref-type="fig" rid="fig10">Figure 10E, E′</xref>, <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1D, E</xref>). Similarly, increased cytoplasmic p90RSK-pT<sup>348</sup> was observed following PMA treatment which was reduced by co-treatment with U0126 (<xref ref-type="fig" rid="fig10">Figure 10F–H′</xref>). The increase in cytoplasmic p90RSK-pT<sup>348</sup> signal, and its reduction by U0126, was significant in both <italic>hai1a</italic> mutants and PMA-treated embryos (<xref ref-type="fig" rid="fig10">Figure 10I, J</xref>).</p><fig-group><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Altered RSK status in <italic>hai1a<sup>hi2217</sup></italic> accounts for epidermal defects.</title><p>(<bold>A, B</bold>) In situ hybridisation of <italic>rps6ka3a</italic> at 24hpf under low- (<bold>A</bold>) and high-power (<bold>B</bold>) magnification showing expression in basal keratinocytes. Open arrowheads in (<bold>B</bold>) indicate borders of EVL cells bisecting nuclei of underlying <italic>rps6ka3</italic>a-positive cells. (<bold>C–H′</bold>) Lateral projected confocal images of the tails of embryos immunostained for p90RSK (Phospho-Thr<sup>348</sup>) (<bold>C–H′</bold>) and TP63 (<bold>C′–H′</bold>). In both the <italic>hai1a<sup>hi2217</sup></italic> (<bold>D, D</bold>′) and 125 ng/ml phorbol 12-myristate 13-acetate (PMA)-treated (<bold>G, G<bold>′</bold></bold>) embryos, there is an increase in cytoplasmic levels of p90RSK (Phospho-Thr<sup>348</sup>) signal above the nuclear only signal seen in WT (<bold>C, C′</bold>) or DMSO (<bold>F, F′</bold>). Treatment with the pERK inhibitor U0126 reduced cytoplasmic levels but did not affect nuclear signal (<bold>E, E′; H, H′</bold>), (<bold>I, J</bold>) Quantification of immunofluorescent intensity of cytoplasmic levels of p90RSK (Phospho-Thr<sup>348</sup>) in basal keratinocytes of tails of 48hpf WT and <italic>hai1a<sup>hi2217</sup></italic>, treated with DMSO or U0126 (<bold>I</bold>), and PMA or PMA plus U0126 (<bold>J</bold>). Nucleus signal was excluded by masking from the DAPI channel. n = 5; t-test; ***p&lt;0.001, **p&lt;0.01, *p&lt;0.05. (<bold>K–N</bold>) Lateral DIC images of <italic>hai1a<sup>hi2217</sup></italic> embryos at 24hpf (<bold>K, L</bold>) and 48hpf (<bold>M, N</bold>) untreated (<bold>K, M</bold>) or treated with 1.2 µM BI-D1870 (<bold>L</bold>) or 9 µM dimethyl fumarate (DMF). Locations of epidermal aggregates and loss of tail fin morphology in <italic>hai1a</italic> mutants, and their rescue by RSK inhibitor treatment are indicated by arrowheads. (<bold>O–Q</bold>) Lateral projected confocal images of the tails of embryos immunostained with antibodies against E-cadherin and TP63in WT (<bold>O</bold>, <bold>P</bold>) and <italic>hai1a<sup>hi2217</sup></italic> treated with DMF (<bold>Q</bold>). (<bold>O′–Q′</bold>) Profile plots of fluorescence distribution across cells of WT (<bold>O</bold>), <italic>hai1a<sup>hi2217</sup></italic> (<bold>P′</bold>), and <italic>hai1a<sup>hi2217</sup></italic> treated with DMF (<bold>Q′</bold>). X-axis represents width of the cell. β-Catenin immunofluorescence intensity (Y-axis) shows majority at cell edge (E-cadherin domain demarcated in light purple) and centre of cell (nucleus demarcated in light green) in WT and rescued <italic>hai11a</italic> mutants, but there is no clear membrane signal in the untreated <italic>hai1a</italic> mutants. Two cells per five larvae were analysed. Scale bars: (<bold>A</bold>, <bold>K</bold>, <bold>N</bold>) = 100 µM; (<bold>B</bold>, <bold>H</bold>) p=20 µM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig10-v2.tif"/></fig><fig id="fig10s1" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 1.</label><caption><title>RSK inhibitors rescue the <italic>hai1a</italic> phenotype.</title><p>(<bold>A, B</bold>) Lateral projected confocal images of the yolk surface of 17hpf WT (<bold>A</bold>) and <italic>hai1a<sup>hi2217/ti251</sup></italic> (<bold>B</bold>) embryos immunostained for p90RSK (Phospho-Thr<sup>348</sup>). (<bold>C</bold>) Quantification of immunofluorescent intensity of cytoplasmic levels of p90RSK (Phospho-Thr<sup>348</sup>) in cells over the yolk of 17hpf WT and <italic>hai1a<sup>hi2217/ti251</sup></italic>. Measurements were limited to keratinocyte cytoplasm by reading at sites between TP63-positive nuclei. n = 9 (three cells from three embryos each); Mann–Whitney test; **p&lt;0.01. (<bold>D–G</bold>) Lateral projected confocal images of the tails of 48hpf <italic>hai1a<sup>hi2217</sup></italic> embryos, untreated (<bold>D, F</bold>) or treated with GFX109203 to inhibit PKC (<bold>E</bold>) or dimethyl fumarate (DMF) (<bold>G</bold>) and then immunostained for p90RSK (Phospho-Thr<sup>348</sup>). Levels of cytoplasmic p90RSK-Thr<sup>348</sup> are reduced by both inhibitors. (<bold>H, I</bold>) Lateral DIC images of <italic>hai1a<sup>hi2217</sup></italic> embryos at 24hpf either untreated (<bold>H</bold>) or treated with 9 µM DMF (<bold>I</bold>). Locations of epidermal aggregates and loss of tail fin morphology in <italic>hai1a</italic> mutants, and their rescue by RSK inhibitor treatment are indicated by arrowheads. (<bold>J</bold>) Proportions of epidermal phenotypes from <italic>hai1a<sup>hi2217/hi2217</sup></italic> × <italic>hai1a<sup>+/hi2217</sup></italic> determined at 24hpf and 48hpf following treatments with DMSO, BI-D1870, or DMF. n = 100; Chi-squared test; ***p&lt;0.001. (<bold>K, L</bold>) Lateral projected confocal images of trunks of 48hpf <italic>hai1a<sup>hi2217</sup></italic> embryos, untreated (<bold>K</bold>) or treated with 9 µM DMF (<bold>L</bold>), and then fluorescently immunostained for TP63. Scale bars: (<bold>A</bold>) = 200 µm; (<bold>D</bold>) = 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig10-figsupp1-v2.tif"/></fig></fig-group><p>If phosphorylation of an RSK protein is required for mediating the pERK epidermal defects in <italic>hai1a</italic> mutants, then inhibition of RSK should rescue the epidermal defects. As morpholino-targeted inhibition of <italic>rps6ka3a</italic> was unsuccessful, we employed established pan-RSK inhibitors BI-D1870 and dimethyl fumarate (<xref ref-type="bibr" rid="bib5">Andersen et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Sapkota et al., 2007</xref>). Dimethyl fumarate treatment reduced the extent of cytoplasmic p90RSK-pT<sup>348</sup> in <italic>hai1a</italic> (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1F, G</xref>). We noted that both inhibitors were able to reduce epidermal aggregates in <italic>hai1a</italic> mutants and restore fin morphology when visualised by DIC or TP63 immunofluorescence (<xref ref-type="fig" rid="fig10">Figure 10K–N</xref>, <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1H, I, K, L</xref>). Reduction of mutant phenotype classes was significant at both 24hpf and 48hpf (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1J</xref>). We then assayed if RSK inhibition can reduce the aberrant cytoplasmic E-cadherin staining in <italic>hai1a</italic> mutant basal keratinocytes and observed that dimethyl fumarate treatment restored membrane localisation of E-cadherin in the mutants (<xref ref-type="fig" rid="fig10">Figure 10O–Q′</xref>). Thus, phosphorylation of RSK proteins is altered in <italic>hai1a</italic> mutants, and their inhibition appears to restore E-cadherin to the membrane and reduce epidermal aggregate formation.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>There are a number of similarities between loss of Hai1a in zebrafish and overexpression of Matriptase in the mouse epidermis, including inflammation, hyperproliferation, and enhanced keratinocyte motility, suggesting conservation of downstream pathways. What the conserved ancestral role of the Matriptase-Hai1 might have been is unclear. Matriptase dysregulation in the mouse is associated with cancer progression (<xref ref-type="bibr" rid="bib34">Martin and List, 2019</xref>). Tumours have long been considered to represent non-healing wounds, and the cellular- and tissue-level phenotypes of <italic>hai1a</italic> have similarities to tumours. Epidermal cells in zebrafish transformed by MAPK activation both promote and respond to inflammation through similar mechanisms to wound responses (<xref ref-type="bibr" rid="bib18">Feng et al., 2010</xref>; <xref ref-type="bibr" rid="bib51">Schäfer and Werner, 2008</xref>). Further, tissue damage of the zebrafish epidermis perturbs osmolarity and releases nucleotides, leading to inflammation and epithelial cell motility, with the resulting phenotypes strikingly similar to <italic>hai1a</italic> mutants (<xref ref-type="bibr" rid="bib15">de Oliveira et al., 2014</xref>; <xref ref-type="bibr" rid="bib16">Enyedi and Niethammer, 2015</xref>; <xref ref-type="bibr" rid="bib19">Gault et al., 2014</xref>; <xref ref-type="bibr" rid="bib22">Hatzold et al., 2016</xref>). Indeed, the tissue responses initiated by loss of zebrafish Hai1a have been previously suggested to represent an early injury response (<xref ref-type="bibr" rid="bib53">Schepis et al., 2018</xref>), whilst PAR2 synergises with P2Y purinergic and EGF receptors to promote cell migration in scratch assays (<xref ref-type="bibr" rid="bib56">Shi et al., 2013</xref>). Thus our analysis supports the previous hypothesis of the Hai1-Matriptase system as a component of tissue injury responses (<xref ref-type="bibr" rid="bib53">Schepis et al., 2018</xref>), which, if inappropriately activated, promotes carcinoma.</p><p>The various molecular pathways known to be activated by Matriptase have not been fully delineated or integrated. Par2 has previously been shown to be required for the <italic>hai1a</italic> phenotype in zebrafish and contributes to the phenotypes of Matriptase overexpression in the mouse. Exactly which heterotrimeric G-protein Par2 is activating in vivo and how this links to phenotypes has not been identified. Our analyses allow us to propose a pathway downstream of Par2 which accounts for both the inflammatory and the epidermal phenotypes (<xref ref-type="fig" rid="fig11">Figure 11</xref>). Firstly, inhibition of Gq rescued both the inflammation and epithelial defects. PAR2 activation of Gq has been documented to occur in many cell types including keratinocytes, where inhibition of Gq and PKC reduces PAR2-mediated Nfκb signalling (<xref ref-type="bibr" rid="bib7">Böhm et al., 1996</xref>; <xref ref-type="bibr" rid="bib21">Goon Goh et al., 2008</xref>; <xref ref-type="bibr" rid="bib32">Macfarlane et al., 2005</xref>). Although we were unable to rescue <italic>hai1a</italic> phenotypes with a PLC inhibitor due to toxicity, genetic sensors demonstrated increased levels of Ca<sup>++</sup> and DAG in <italic>hai1a</italic> epidermis. Our analysis demonstrated that the different products of PIP2 hydrolysis appear to invoke the two main <italic>hai1a</italic> phenotypes to different extents. IP<sub>3</sub>R-dependent calcium release in <italic>hai1a</italic> epidermis was required for Duox activity, high hydrogen peroxide levels, and, later, increased NfkB signalling. Reduction of these attenuated the inflammatory, but not epithelial, defects. Conversely, inhibiting the DAG receptor, PKC, rescued the epithelial phenotypes, and the inflammation slightly. The DAG analogue, PMA, phenocopied the epidermal defects of <italic>hai1a</italic> mutants but also increased H<sub>2</sub>O<sub>2</sub>, NfkB, and neutrophil inflammation, indicating that PKC activation may be sufficient, but not necessary, for inflammation. This is in line with known activation of Duox and IKK by PKC (<xref ref-type="bibr" rid="bib45">Rigutto et al., 2009</xref>; <xref ref-type="bibr" rid="bib65">Turvey et al., 2014</xref>). In addition, expression of activated Ras in zebrafish keratinocytes has been shown to lead to H<sub>2</sub>O<sub>2</sub> release and neutrophil attraction (<xref ref-type="bibr" rid="bib18">Feng et al., 2010</xref>). Thus, there is likely to be dual contribution to the inflammatory phenotype from IP3 and DAG. It is important to stress however that the inflammation is not simply a result of epithelial defects or an overt loss of barrier. Firstly, we see increase in Ca<sup>++</sup> and H<sub>2</sub>O<sub>2</sub> very early in the epidermis prior to skin defects. Secondly, barrier assays failed to conclusively show a broad increase in permeability. Finally, rescue of epithelial defects by PKC and pERK inhibition did not fully rescue the inflammation. We conclude in our model that DAG contributes to both aspects of the phenotype, but IP<sub>3</sub> promotes only the inflammation.</p><fig id="fig11" position="float"><label>Figure 11.</label><caption><title>Model of pathway-activated downstream of Hai1 and Matriptase.</title><p>Proposed model of pathways downstream of Hai1 which drives chronic and acute sterile inflammation (red) and epithelial motility (blue). A previously defined transactivation of EGFR is also integrated. Other pathways known to act downstream of Matriptase, involving cMet, PI3K, AKT, and mTOR, are not shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-fig11-v2.tif"/></fig><p>Seminal experiments in transgenic mice overexpressing Matriptase in the epidermis and treated with a DMBA/PMA regime concluded that Matriptase and PMA activate functionally similar carcinoma promoting pathways (<xref ref-type="bibr" rid="bib31">List et al., 2005</xref>). Our subsequent analysis suggests that this would include the MAPK pathway as we see increased phosphorylated-ERK in the epidermis of both <italic>hai1a</italic> mutants and also PMA-treated embryos. That we can rescue the epithelial defects using a MEK inhibitor indicated that this increase in epidermal pERK is likely critical to the phenotype. The MAPK pathway is known to regulate cell motility (<xref ref-type="bibr" rid="bib63">Tanimura and Takeda, 2017</xref>). In the zebrafish epidermis, misexpression of activated MEK2 generated papillomas with remarkable resemblance to the epidermal aggregates in <italic>hai1a</italic> mutants (<xref ref-type="bibr" rid="bib11">Chou et al., 2015</xref>), and which are not overtly proliferative. In astrocytes and oesophageal or breast tumour cell lines, PAR2 stimulates migration and invasiveness through MAPK/ERK, activation of which required Gq and PIP2 hydrolysis (<xref ref-type="bibr" rid="bib23">Jiang et al., 2004</xref>; <xref ref-type="bibr" rid="bib36">McCoy et al., 2010</xref>; <xref ref-type="bibr" rid="bib38">Morris et al., 2006</xref>; <xref ref-type="bibr" rid="bib55">Sheng et al., 2019</xref>).</p><p>One of the main molecular defects defined for zebrafish <italic>hai1a</italic> is the removal of adherens junction proteins from the membrane (<xref ref-type="bibr" rid="bib8">Carney et al., 2007</xref>). MAPK signalling has been shown to reduce E-cadherin expression at adherens junctions and promote cytoplasmic accumulation through phosphorylation of the effector, RSK (<xref ref-type="bibr" rid="bib9">Čáslavský et al., 2013</xref>). Like Matriptase, activation of RSK2 is associated with tumour progression, promoting invasiveness and metastasis of glioblastomas and head and neck squamous cell carcinomas (<xref ref-type="bibr" rid="bib24">Kang et al., 2010</xref>; <xref ref-type="bibr" rid="bib59">Sulzmaier et al., 2016</xref>). Promotion of invasiveness has also been noted for activated RSK1, which promotes invasion of melanoma clinically as well as in vitro and zebrafish melanoma models (<xref ref-type="bibr" rid="bib49">Salhi et al., 2015</xref>). Intriguingly, proximity protein labelling has identified p120-catenin as a target of RSK phosphorylation. This catenin promotes cell-cell adhesion by stabilising cadherins at junctions, a function inhibited by RSK phosphorylation (<xref ref-type="bibr" rid="bib37">Méant et al., 2020</xref>). More broadly, RSK2 activity promotes cell motility through other mechanisms, including inactivation of Integrins and activation of the RhoGEF, LARG (<xref ref-type="bibr" rid="bib20">Gawecka et al., 2012</xref>; <xref ref-type="bibr" rid="bib57">Shi et al., 2018</xref>). Thus, we propose that pERK signalling, through RSK members, significantly contributes to dissolution of adherens junctions and the <italic>hai1a</italic> epidermal phenotype. We observed increased pERK in the cytoplasm and also the nucleus of keratinocytes, with comparatively more nuclear levels in periderm cells. Thus, whilst RSKs are phosphorylated by pERK, it is also likely that other cytoplasmic and also nuclear targets, such as cFos and Ets transcription factors, may also be activated, and that there are underlying transcriptional changes in <italic>hai1a</italic> mutants. It is not clear why pERK shows slightly different subcellular localisation patterns between the two different epidermal layers, but the two layers do respond differently to ErbB2 inhibition (<xref ref-type="bibr" rid="bib53">Schepis et al., 2018</xref>), whilst calcium is recently described to alter nuclear shuttling of pERK (<xref ref-type="bibr" rid="bib12">Chuderland et al., 2020</xref>).</p><p>Our model for how Matriptase invokes cellular responses is highly likely to be incomplete. Indeed, others have indicated MMPs, HB-EGF, EGFR, and AKT and are downstream of Matriptase and PAR2 function (<xref ref-type="bibr" rid="bib31">List et al., 2005</xref>; <xref ref-type="bibr" rid="bib53">Schepis et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">Darmoul et al., 2004</xref>; <xref ref-type="bibr" rid="bib13">Chung et al., 2013</xref>; <xref ref-type="bibr" rid="bib41">Rattenholl et al., 2007</xref>). Furthermore, Matriptase promotes HGF–cMet signalling in mouse (<xref ref-type="bibr" rid="bib61">Szabo et al., 2011</xref>). We do not think that these conflict with our model but will interface with it. A number of reports have demonstrated that PI3K/AKT and MEK/ERK function in parallel downstream of PAR2 (<xref ref-type="bibr" rid="bib55">Sheng et al., 2019</xref>; <xref ref-type="bibr" rid="bib62">Tanaka et al., 2008</xref>; <xref ref-type="bibr" rid="bib66">van der Merwe et al., 2009</xref>). Furthermore, there is evidence that PKC activates both MEK/ERK and EGFR independently following PAR2 stimulation, and that PI3K is activated by PAR2 via Gq (<xref ref-type="bibr" rid="bib68">Wang and DeFea, 2006</xref>; <xref ref-type="bibr" rid="bib1">Al-Ani et al., 2010</xref>). Cell identity, subcellular localisation, β-arrestin scaffolding, and biased agonism/antagonism are known to generate alternative downstream outputs from PAR2 (<xref ref-type="bibr" rid="bib69">Zhao et al., 2014</xref>). To understand fully the roles of Matriptase and PAR2 in epithelial homeostasis and carcinoma, it will be critical to map how, when, and where they activate different downstream pathways.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Gene (<italic>Danio rerio</italic>)</td><td><italic>hai1a</italic></td><td>GenBank</td><td>NM_213152</td><td><italic>=spint1a</italic></td></tr><tr><td>Gene (<italic>Danio rerio</italic>)</td><td><italic>matriptase1a</italic></td><td>GenBank</td><td>NM_001040351</td><td><italic>=st14</italic> a</td></tr><tr><td>Gene (<italic>Danio rerio</italic>)</td><td><italic>duox</italic></td><td>GenBank</td><td>XM_017354273</td><td><italic>=dual oxidase</italic></td></tr><tr><td>Gene (<italic>Danio rerio</italic>)</td><td><italic>ikbkg</italic></td><td>GenBank</td><td>NM_001014344</td><td><italic>=ikky</italic> <break/><italic>=nemo</italic></td></tr><tr><td>Gene (<italic>Danio rerio</italic>)</td><td><italic>nfkbiaa</italic></td><td>GenBank</td><td>NM_213184</td><td><italic>=ikbaa</italic></td></tr><tr><td>Gene (<italic>Danio rerio</italic>)</td><td><italic>rps6ka3a</italic></td><td>GenBank</td><td>NM_212786</td><td><italic>=RSK2a</italic> <break/><italic>=p90RSK2a</italic></td></tr><tr><td>Gene (<italic>Danio rerio</italic>)</td><td><italic>tp63</italic></td><td>GenBank</td><td>NM_152986</td><td><italic>=delta</italic> Np63</td></tr><tr><td>Strain, strain background (<italic>Escherichia coli</italic>)</td><td>Top10</td><td>Invitrogen</td><td>C404010</td><td>Chemical competent cells</td></tr><tr><td>Strain, strain background (<italic>Danio rerio</italic>)</td><td>AB</td><td>ZIRC</td><td/><td>Wild-type strain</td></tr><tr><td>Strain, strain background (<italic>Danio rerio</italic>)</td><td>TL</td><td>ZIRC</td><td/><td>Wild-type strain</td></tr><tr><td>Genetic reagent (<italic>Danio rerio</italic>)</td><td><italic>Tg(mpx:EGFP)<sup>i114</sup></italic></td><td>Uni of Sheffield <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/16926288/">16926288</ext-link></td><td>ZFIN ID: <break/>ZDB-ALT-070118-2</td><td/></tr><tr><td>Genetic reagent (<italic>Danio rerio</italic>)</td><td><italic>Tg(fli1:EGFP)<sup>y1</sup></italic></td><td>ZIRC <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/16671106/">16671106</ext-link></td><td>ZFIN ID: <break/>ZDB-ALT-011017-8</td><td/></tr><tr><td>Genetic reagent (<italic>Danio rerio</italic>)</td><td><italic>hai1a<sup>fr26</sup></italic></td><td>Hammerschmidt lab; Max Planck Freiburg <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/31819976/">31819976</ext-link></td><td>ZFIN ID: <break/>ZDB-ALT-200618-2</td><td>=<italic>spint1a<sup>fr26</sup></italic></td></tr><tr><td>Genetic reagent (<italic>Danio rerio</italic>)</td><td><italic>hai1a<sup>hi2217</sup></italic></td><td>Nancy Hopkins lab; Massachusetts Institute of Technology <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17728346/">17728346</ext-link></td><td>ZFIN ID: <break/>ZDB-ALT-040924-4</td><td><italic>=spint1a<sup>hi2217Tg</sup></italic></td></tr><tr><td>Genetic reagent (<italic>Danio rerio</italic>)</td><td><italic>ddf<sup>ti251</sup></italic></td><td>Nuesslein-Volhard lab; Max Planck Tuebingen PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/9007245/">9007245</ext-link></td><td>ZFIN ID: <break/>ZDB-ALT-980203-1462</td><td>=<italic>dandruff</italic> spint1a<sup>ti251</sup> <break/>=<italic>=hai1a<sup>ti251</sup></italic></td></tr><tr><td>Genetic reagent (<italic>Danio rerio</italic>)</td><td><italic>ddf<sup>t419</sup></italic></td><td>Nuesslein-Volhard lab; Max Planck Tuebingen <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/9007245/">9007245</ext-link></td><td/><td>=<italic>dandruff</italic> spint1a<sup>t419</sup> <break/>=<italic>=hai1a<sup>t419</sup></italic></td></tr><tr><td>Genetic reagent (<italic>Danio rerio</italic>)</td><td><italic>st14a<sup>sq10</sup></italic></td><td>Our lab <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/3164615/">31645615</ext-link></td><td>ZFIN ID: <break/>ZDB-ALT-200219-5</td><td/></tr><tr><td>Genetic reagent (<italic>Danio rerio</italic>)</td><td><italic>Tg(6xNFkB:EGFP)<sup>nc1</sup></italic></td><td>Rawls lab <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21439961/">21439961</ext-link></td><td>ZFIN ID: <break/>ZDB-ALT-120409-6</td><td/></tr><tr><td>Genetic reagent (<italic>Danio rerio</italic>)</td><td><italic>Tg(krtt1c19e:LY-Tomato)<sup>sq16</sup></italic></td><td>Our lab. Lee et al: <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/24400120/">24400120</ext-link></td><td>ZFIN ID: <break/>ZDB-ALT-140424-2</td><td/></tr><tr><td>Genetic reagent (<italic>Danio rerio</italic>)</td><td><italic>Tg(actb2:GCaMP6s, myl7:mCherry)<sup>lkc2</sup></italic></td><td>This paper</td><td/><td>Plasmid from Solnica-Krezel Lab. Injected with Tol2 RNA to make line</td></tr><tr><td valign="top">Antibody</td><td>Chicken anti-eGFP antibody</td><td>Abcam</td><td>ab13970, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_300798">AB_300798</ext-link></td><td>1:500</td></tr><tr><td valign="top">Antibody</td><td>Rabbit anti-eGFP</td><td>Torrey Pines Biolabs</td><td>Tp401 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10013661">AB_10013661</ext-link></td><td>1:500</td></tr><tr><td valign="top">Antibody</td><td>Rabbit anti-FITC</td><td>Thermo Fisher Scientific</td><td>71-1900 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2533978">AB_2533978</ext-link></td><td>1:200</td></tr><tr><td valign="top">Antibody</td><td>Rabbit anti-p90RSK (Phospho-Thr<sup>348</sup>)</td><td>GenScript</td><td>A00487</td><td>1:100</td></tr><tr><td valign="top">Antibody</td><td>Rabbit anti-beta catenin</td><td>Abcam</td><td>ab6302 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_305407">AB_305407</ext-link></td><td>1:200</td></tr><tr><td valign="top">Antibody</td><td>Mouse anti-E-cadherin</td><td>BD Biosciences</td><td>610181 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_397580">AB_397580</ext-link></td><td>1:200</td></tr><tr><td valign="top">Antibody</td><td>Mouse anti-Tp63</td><td>Biocare Medical</td><td>CM163 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10582730">AB_10582730</ext-link></td><td>1:200</td></tr><tr><td valign="top">Antibody</td><td>Rabbit anti-phospho-p44/42 MAPK (Erk1/2) (Thr<sup>202</sup>/Tyr<sup>204</sup>)</td><td>Cell Signaling Technology</td><td>Cat# 4370, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2315112">AB_2315112</ext-link></td><td>1:100</td></tr><tr><td valign="top">Antibody</td><td>Rabbit anti-p44/42 MAPK (Erk1/2)</td><td>Cell Signaling Technology</td><td>Cat# 9102, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_330744">AB_330744</ext-link></td><td>1:100</td></tr><tr><td valign="top">Antibody</td><td>Alexa Fluor-488 Donkey anti-rabbit</td><td>Life Technologies</td><td>A21206 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2535792">AB_2535792</ext-link></td><td>1:700</td></tr><tr><td valign="top">Antibody</td><td>Alexa Fluor-647 Donkey anti-rabbit</td><td>Life Technologies</td><td>A31573 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_253618">AB_253618</ext-link></td><td>1:700</td></tr><tr><td valign="top">Antibody</td><td>Alexa Fluor-546 Donkey anti-mouse</td><td>Life Technologies</td><td>A10036 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2534012">AB_2534012</ext-link></td><td>1:700</td></tr><tr><td valign="top">Antibody</td><td>Alexa Fluor-488 Goat anti-chicken</td><td>Life Technologies</td><td>A11039 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2534096">AB_2534096</ext-link></td><td>1:700</td></tr><tr><td>Recombinant DNA reagent</td><td>pCS2+-PKCδ-GFP</td><td>Amaya Lab, Uni of Manchester <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/15866160/">15866160</ext-link></td><td/><td>For making <italic>PKCd-GFP</italic> RNA</td></tr><tr><td>Recombinant DNA reagent</td><td>pT3Ts-Tol2</td><td>Ekker Lab, Mayo Clinic <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17096595/">17096595</ext-link></td><td>Addgene Plasmid #31831 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_31831">Addgene_31831</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pCS2+-GCaMP6s</td><td>Solnica-Krezel Lab, Washington University School of Medicine, St. Louis, MO</td><td/><td>For making <italic>GCaMP6s</italic> RNA</td></tr><tr><td>Recombinant DNA reagent</td><td>p(<italic>actb2:GCaMP6s, myl7:mCherry</italic>)</td><td>Solnica-Krezel Lab, Washington University School of Medicine, St. Louis, MO. <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28322738/">28322738</ext-link></td><td/><td>For making stable transgenic line</td></tr><tr><td>Sequence-based reagent</td><td><italic>duox</italic> morpholino</td><td>GeneTools</td><td>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/19494811/">19494811</ext-link></td><td>5′ AGTGAATTAGAGAAATGCACCTTTT 3′ (0.4 mM)</td></tr><tr><td>Sequence-based reagent</td><td><italic>p53</italic> morpholino</td><td>GeneTools</td><td>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/19494511/">19494811</ext-link></td><td>5′ <break/>GCGCCATTGCTTTGCAAGAATTG 3′ (0.2 mM)</td></tr><tr><td>Sequence-based reagent</td><td>Oligo(dT)12–18 Primer</td><td>Invitrogen</td><td>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18418012/">18418012</ext-link></td><td/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>nfkbiaa</italic></td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">F-5′ AGACGCAAAGGAGCAGTGTAG 3′ <break/>R- 5′ TGTGTGTCTGCCGAAGGTC 3′</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>eef1a1l1</italic></td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">F′-5′ CTGGAGGCCAGCTCAAACAT 3′ <break/>R-5′ ATCAAGAAGAGTAGTACCGCTAGCATTAC 3′</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>rps6ka3a</italic> in situ probe</td><td valign="top">This paper</td><td valign="top">PCR primers for cloning probe</td><td valign="top">F′-5′ ATACTCCAGTCCCACCGGA 3′ <break/>R- 5′TGGTGATGATGGTAGACTCGC 3′</td></tr><tr><td valign="top">Peptide, recombinant protein</td><td>Proteinase K</td><td>Thermo Scientific</td><td>EO0491</td><td>0.5 μg/μl</td></tr><tr><td>Commercial assay or kit</td><td>SuperScript III Reverse Transcriptase</td><td>Invitrogen</td><td>18080093</td><td/></tr><tr><td>Commercial assay or kit</td><td>TRIzol Reagent</td><td>Invitrogen</td><td>15596026</td><td/></tr><tr><td>Commercial assay or kit</td><td>GoTaq G2 Green Master Mix</td><td>Promega</td><td>M7823</td><td>Functions used: <break/>TrackMate <break/>Reslice <break/>Average Intensity</td></tr><tr><td>Commercial assay or kit</td><td>iTaq Universal SYBR Green Supermix</td><td>Bio-Rad</td><td>1725121</td><td>Functions used: <break/>Spot</td></tr><tr><td>Commercial assay or kit</td><td>mMESSAGE mMACHINE SP6 Transcription Kit</td><td>Invitrogen</td><td>AM1340</td><td>Tests: <break/>Student’s t-test, <break/>Chi-squared test, <break/>Mann–Whitney test, <break/>ANOVA with Bonferroni or Dunn’s post-tests</td></tr><tr><td>Commercial assay or kit</td><td>mMESSAGE mMACHINE T3 Transcription Kit</td><td>Invitrogen</td><td>AM1348</td><td/></tr><tr><td>Commercial assay or kit</td><td>MEGAshortscript T7 Transcription Kit</td><td>Invitrogen</td><td>AM1350</td><td/></tr><tr><td>Commercial assay or kit</td><td>pGEM-T Easy</td><td>Promega</td><td>A137A</td><td/></tr><tr><td>Commercial assay or kit</td><td>pCR 2.1-TOPO TA vector</td><td>Invitrogen</td><td>K450040</td><td/></tr><tr><td>Commercial assay or kit</td><td>QIAquick PCR Purification Kit</td><td>Qiagen</td><td>28104</td><td/></tr><tr><td valign="top">Commercial assay or kit</td><td>DIG RNA Labeling Kit</td><td>Roche</td><td>11175025910</td><td/></tr><tr><td valign="top">Commercial assay or kit</td><td>SP6 RNA Polymerase</td><td>Roche</td><td>10 810 274 001</td><td/></tr><tr><td valign="top">Commercial assay or kit</td><td>NBT/BCIP Stock Solution</td><td>Roche</td><td>11681451001</td><td/></tr><tr><td>Chemical compound, drug</td><td>Diphenyleneiodonium chloride</td><td>Sigma-Aldrich</td><td>D2926</td><td>40 μM</td></tr><tr><td>Chemical compound, drug</td><td>Thapsigargin</td><td>Sigma-Aldrich</td><td>T9033</td><td>6.25 μM</td></tr><tr><td>Chemical compound, drug</td><td>Bisindolylmaleimide I (GF109203X)</td><td>Selleckchem</td><td>S7208</td><td>85 μM</td></tr><tr><td>Chemical compound, drug</td><td>YM-254890</td><td>FocusBiomolecules</td><td>10-1590-0100</td><td>32 μM</td></tr><tr><td>Chemical compound, drug</td><td>2-Aminoethyl diphenylborinate</td><td>Sigma-Aldrich</td><td>D9754</td><td>2.5 μM</td></tr><tr><td>Chemical compound, drug</td><td>BI-D1870</td><td>Axon Medchem</td><td>Axon-1528</td><td>1.2 μM</td></tr><tr><td>Chemical compound, drug</td><td>Dimethyl fumarate</td><td>Sigma-Aldrich</td><td>242926</td><td>9 μM</td></tr><tr><td>Chemical compound, drug</td><td>Phorbol 12-myristate 13-acetate</td><td>Sigma-Aldrich</td><td>P8139</td><td>37.5 or 125 ng/ml</td></tr><tr><td>Chemical compound, drug</td><td>U0126</td><td>Cell Signaling Technology</td><td>9903</td><td>100 μM</td></tr><tr><td>Chemical compound, drug</td><td>PD184352 (CI-1040)</td><td>Selleckchem</td><td>S1020</td><td>1.3 μM</td></tr><tr><td>Chemical compound, drug</td><td>DAPI (4′,6-diamidino-2-phenylindole, dihydrochloride)</td><td valign="top">Invitrogen</td><td valign="top">D1306</td><td>5 µg/ml</td></tr><tr><td>Chemical compound, drug</td><td>Penta-fluorobenzenesulfonyl fluorescein</td><td>Cayman Chemicals</td><td>10005983</td><td>12.5 μM</td></tr><tr><td valign="top">Chemical compound, drug</td><td><italic>Fluorescein isothiocyanate–dextran</italic></td><td>Sigma-Aldrich</td><td>FD4</td><td>2.5 mg/ml</td></tr><tr><td>Software, algorithm</td><td>Fiji (ImageJ 1.52p)</td><td>NIH</td><td><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/">https://imagej.nih.gov/</ext-link></td><td>Functions used: <break/>TrackMate <break/>Reslice <break/>Average Intensity</td></tr><tr><td>Software, algorithm</td><td>Imaris 9.6.0</td><td>Oxford Instruments</td><td/><td>Functions used: <break/>Spot</td></tr><tr><td>Software, algorithm</td><td>Prism 9.1.1</td><td>GraphPad</td><td/><td>Tests: <break/>Student’s t-test, <break/>Chi-squared test, <break/>Mann–Whitney test, <break/>ANOVA with Bonferroni or Dunn’s post-tests</td></tr><tr><td>Software, algorithm</td><td>Photoshop 22.1.1 release</td><td>Adobe</td><td/><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Zebrafish husbandry and lines</title><p>Fish were housed at the IMCB and the NTU zebrafish facilities under IACUC numbers #140924 and #A18002, respectively, and according to the guidelines of the National Advisory Committee for Laboratory Animal Research. Embryos were derived by natural crosses and staged as per <xref ref-type="bibr" rid="bib28">Kimmel et al., 1995</xref> and raised in 0.5× E2 medium (7.5 mM NaCl, 0.25 mM KCl, 0.5 mM MgSO<sub>4</sub>, 75 μM KH<sub>2</sub>PO<sub>4</sub>, 25 μM Na<sub>2</sub>HPO<sub>4</sub>, 0.5 M CaCl<sub>2</sub>, 0.35 mM NaHCO<sub>3</sub>). Anaesthesia was administered in E2 medium (embryos) or fish tank water (adults) using 0.02% pH 7.0 buffered Tricaine MS-222 (Sigma). The <italic>hai1a/ddf</italic> alleles used were <italic>hai1a<sup>hi2217</sup></italic>, <italic>hai1a<sup>fr26</sup></italic>, <italic>ddf<sup>ti251</sup></italic>, and <italic>ddf<sup>t419</sup></italic>. The <italic>st14a<sup>sq10</sup></italic> allele was generated previously (<xref ref-type="bibr" rid="bib30">Lin et al., 2019</xref>). For imaging neutrophils and keratinocytes, the transgenic lines <italic>Tg(mpx:EGFP)<sup>i114</sup></italic> (<xref ref-type="bibr" rid="bib44">Renshaw et al., 2006</xref>) and <italic>Tg(krtt1c19e:lyn-tdtomato)<sup>sq16</sup></italic> (<xref ref-type="bibr" rid="bib29">Lee et al., 2014</xref>) were used, whilst early leukocytes were imaged with <italic>Tg(fli1:EGFP)<sup>y1</sup></italic> (<xref ref-type="bibr" rid="bib43">Redd et al., 2006</xref>). To image NfkB pathway activity, the <italic>Tg(6xHsa.NFKB:EGFP)<sup>nc1</sup></italic> sensor line was used (<xref ref-type="bibr" rid="bib26">Kanther et al., 2011</xref>). Calcium imaging was performed by injection of <italic>GCaMP6s</italic> RNA (see below) or using a <italic>Tg(actb2:GCaMP6s, myl7:mCherry)<sup>lkc2</sup></italic> stable transgenic line, generated via plasmid (<xref ref-type="bibr" rid="bib10">Chen et al., 2017</xref>) and <italic>Tol2</italic> RNA co-injection.</p></sec><sec id="s4-2"><title>Genomic DNA and RNA extraction, reverse transcription, and PCR</title><p>Adult fin clips or embryos were isolated following anaesthesia, and genomic DNA extracted by incubation at 55°C for 4 hr in Lysis buffer (10 mM Tris pH 8.3, 50 mM KCl, 0.3% Tween20, 0.3% Nonidet P-40, 0.5 µg/µl Proteinase K). PCRs were performed using GoTaq (Promega) on a Veriti thermal cycler (Applied Biosystems) and purified with a PCR purification kit (Qiagen). TRIzol (Invitrogen) was used for RNA extraction following provided protocol, and cDNA generated from 1 µg total RNA using SuperScript III Reverse Transcriptase (Invitrogen) with Oligo(dT)12-18 primer. For qPCR, iTaq SYBR green (Bio-Rad) was used to amplify, with reaction dynamics measured on a Bio-Rad CFX96 Real-Time PCR Detection System. For measuring <italic>nfkbiaa</italic> mRNA by qPCR, the following primers (5′ to 3′) were used to amplify a region encoded on exons 4 and 5: F-<named-content content-type="sequence">AGACGCAAAGGAGCAGTGTAG</named-content>, R-<named-content content-type="sequence">TGTGTGTCTGCCGAAGGTC</named-content>. Reference gene was <italic>eef1a1l1</italic> and the primers used amplified between exon 3 to 4: F-<sc><named-content content-type="sequence">CTGGAGGCCAGCTCAAACAT</named-content></sc>, R- <named-content content-type="sequence">ATCAAGAAGAGTAGTACCGCTAGCATTAC</named-content>.</p></sec><sec id="s4-3"><title>RNA synthesis</title><p>RNAs for <italic>GCaMP6s</italic> and <italic>PKCδ-GFP</italic> were synthesised from pCS2-based plasmids containing the respective coding sequences (<xref ref-type="bibr" rid="bib58">Sivak et al., 2005</xref>; <xref ref-type="bibr" rid="bib10">Chen et al., 2017</xref>). These were linearised with <italic>Not</italic>I (NEB), and RNA in vitro transcribed with mMESSAGE mMACHINE SP6 Transcription Kit (Ambion). RNA for <italic>Tol2</italic> was generated from the pT3Ts-Tol2 plasmid, linearised with <italic>Sma</italic>I (NEB), and transcribed with the mMESSAGE mMACHINE T3 Transcription Kit (Ambion). RNA for injection was purified by lithium chloride precipitation.</p></sec><sec id="s4-4"><title>Embryo injection and morpholino</title><p>Embryos were aligned on an agarose plate and injected at the one-cell stage with RNA or morpholino diluted in Phenol Red and Danieau’s buffer using a PLI-100 microinjector (Harvard Apparatus). Injection needles were pulled from borosilicate glass capillaries (0.5 mm inner diameter, Sutter) on a Sutter P-97 micropipette puller. The Duox morpholino (<named-content content-type="sequence">AGTGAATTAGAGAAATGCACCTTTT</named-content>) was purchased from GeneTools and injected at 0.4 mM with 0.2 mM of the tp53 morpholino (<named-content content-type="sequence">GCGCCATTGCTTTGCAAGAATTG</named-content>).</p></sec><sec id="s4-5"><title>TALEN mutagenesis</title><p>To generate the <italic>ikbkg</italic> mutant, TALEN vectors targeting the sequence <named-content content-type="sequence">ATGGAGGGCTGG</named-content> in second exon were designed and constructed by ToolGen (<ext-link ext-link-type="uri" xlink:href="http://toolgen.com">http://toolgen.com</ext-link>). TALEN vectors were linearised with <italic>PvuII</italic> (NEB) and purified using a PCR purification kit (Qiagen), and then used for in vitro transcription with the MEGAshortscript T7 kit (Ambion). About 170–300 pg of supplied ZFN RNAs or purified TALEN RNAs were then injected into one-cell stage WT zebrafish embryos, which were raised to 24 hr, then genomic DNA extracted.</p><p>For detection of fish with edited loci, PCR was performed on genomic DNA of injected fish with primers flanking the target site, cloned by TA cloning into pGEMT-Easy (Promega) or pCR2.1-TOPO-TA (Invitrogen) and individual clones sequenced to establish efficiency. Other embryos were raised to adulthood and their offspring were similarly genotyped to identify founder mutants.</p></sec><sec id="s4-6"><title>Small-molecule treatment</title><p>All compounds for treating embryos were dissolved in DMSO, diluted in 0.5× E2 Embryo Medium and embryos treated by immersion. The compounds, and concentrations used, with catalogue numbers were diphenyleneiodonium chloride (DPI), 40 µM (D2926, Sigma); thapsigargin, 6.25 µM (T9033, Sigma); bisindolylmaleimide I (GF109203X), 85 µM (S7208, Selleckchem); YM-254890, 32 µM (10-1590-0100, Focus Biomolecules); 2-aminoethyl diphenylborinate (2-APB), 2.5 µM (D9754, Sigma), BI-D1870, 1.2 µM (Axon-1528, Axon Medchem); dimethyl fumarate, 9 µM (242926, Sigma); phorbol 12-myristate 13-acetate (PMA), 37.5 or 125 ng/ml (P8139, Sigma); U0126, 100 µM (9903, Cell Signaling Technology); PD184352 (CI-1040), 1.3 µM (S1020, Selleckchem). Unless otherwise stated, controls for all experiments were exposed to 0.5% DMSO carrier in 0.5× E2 Embryo Medium.</p></sec><sec id="s4-7"><title>Proteomic analysis</title><p>Batches of 100 WT, <italic>ddf<sup>t419</sup></italic>, and <italic>ddf<sup>ti251</sup></italic> embryos were collected at 24 hr and 48 hr, dechorionated, deyolked, and protein extracted as per <xref ref-type="bibr" rid="bib3">Alli Shaik et al., 2014</xref>. Protein was precipitated in 100% methanol at 4°C, then resuspended in 2-D cell lysis buffer (30 mM Tris-HCl, pH 8.8, containing 7 M urea, 2 M thiourea, and 4% CHAPS). 2-D DIGE and mass spectrometry protein identification was performed by Applied Biomics (Hayward, CA). Protein samples were labelled with either Cy2, Cy3, or Cy5, mixed, and then subjected to 2-D DIGE to separate individual proteins. Gels were scanned using Typhoon TRIO (Amersham BioSciences) and analysed by Image QuantTL and DeCyder (ver. 6.5) software (GE-Healthcare). Spots with more than 1.5-fold change were picked, in-gel trypsin digested, and protein identification performed by MALDI-TOF mass spectrometry and MASCOT search engine in the GPS Explorer software (Matrix Science).</p></sec><sec id="s4-8"><title>In situ hybridisation</title><p>A probe corresponding to the final 1078 bp of <italic>rps6ka3a</italic> (<italic>RSK2a;</italic> NM_212786.1) was generated by cloning a PCR-derived cDNA fragment into in pGEMT-Easy (Promega), linearising with <italic>ApaI</italic> (NEB) and transcribing a DIG probe with SP6 RNA polymerase (Roche). Whole-mount in situ hybridisation developed with NBT/BCIP (Roche) was performed as described (<xref ref-type="bibr" rid="bib64">Thisse and Thisse, 2008</xref>).</p></sec><sec id="s4-9"><title>Immunofluorescent, dye staining, and TUNEL</title><p>For antibody staining, embryos were fixed in 4% paraformaldehyde overnight at 4°C and then washed in PBT (0.1% Triton in PBS), permeabilised in −20°C acetone for 7 min, washed in PBT, blocked for 3 hr in Block solution (PBT supplemented with 4% BSA and 1% DMSO), then incubated overnight at 4°C with primary antibody diluted in Block solution, washed extensively in PBT, re-blocked in Block solution, then incubated overnight at 4°C with fluorescent secondary antibody diluted in Block solution. Following extensive PBT washing, embryos were cleared in 80% glycerol/PBS before imaging. Primary antibodies used and their dilutions are as follows: Chicken anti-eGFP antibody, 1:500 (ab13970, Abcam), Rabbit anti-eGFP, 1:500 (Tp401, Torrey Pines Biolabs), Rabbit anti-FITC, 1:200 (#71-1900, Thermo Fisher), Rabbit anti-beta catenin, 1:200 (ab6302, Abcam), Mouse anti-E-cadherin, 1:200 (#610181, BD Biosciences), Mouse anti-Tp63, 1:200 (CM163, Biocare Medical), Rabbit anti-phospho-p44/42 MAPK (Erk1/2) (Thr<sup>202</sup>/Tyr<sup>204</sup>), 1:100 (#4370, Cell Signaling Technology), Rabbit anti-p44/42 MAPK (Erk1/2), 1:100 (#9102, Cell Signaling Technology), and Rabbit anti-p90RSK (Phospho-Thr<sup>348</sup>), 1:100 (A00487, GenScript). All secondary antibodies were purchased from Invitrogen and used at 1:700 and were Alexa Fluor-488 Donkey anti-rabbit (A21206), Alexa Fluor-647 Donkey anti-rabbit (A31573), Alexa Fluor-546 Donkey anti-mouse (A10036), and Alexa Fluor-488 Goat anti-chicken (A-11039). Nuclei were counterstained using 5 µg/ml of DAPI (4',6-diamidino-2-phenylindole, dihydrochloride; D1306, Invitrogen) added during secondary antibody incubation.</p><p>To stain hydrogen peroxide, embryos were incubated for 60 min at room temperature with 12.5 µM PFBSF (#10005983, Cayman Chemicals), then rinsed in Embryo Medium, anaesthetised, and imaged.</p><p>Fluorescent TUNEL staining was performed using the Fluorescein In Situ Cell Death Detection Kit (11684795910, Roche), with the fluorescein detected by antibody staining using rabbit anti-FITC, and co-immunostained for TP63 and eGFP. Epidermal permeability assays were conducted by immersing 36hpf embryos in 2.5 mg/ml fluorescein isothiocyanate-dextran 3–5 kDa (Sigma) or 0.075% methylene blue for 30 min and then destained in E2 medium.</p></sec><sec id="s4-10"><title>Microscopy and statistical analysis</title><p>Still and timelapse imaging was performed on upright Zeiss AxioImager M2, Zeiss Light-sheet Z.1, upright Zeiss LSM800 Confocal Microscope or Zeiss AxioZoom V16 microscopes. Embryos were mounted in 1.2% Low Melting Point Agarose (Mo Bio Laboratories) in 0.5× E2 medium in 35 mm glass-bottom imaging dishes (MatTek) or in a 1 mm inner diameter capillary for light-sheet timelapse. When imaging was performed on live embryos, the embryo media were supplemented with buffered 0.02% Tricaine and imaging conducted at 25°C. Image processing was done using Zen 3.1 software (Zeiss), Fiji (ImageJ, ver. 1.52p), or Imaris (Bitplane) and compiled using Photoshop 2020 (Adobe). Neutrophils were tracked with TrackMate in Fiji or using the Spot function in Imaris. Kymographs were generated using the Reslice function in Fiji following generation of a line of interest across image. Fluorescence intensities were calculated using the Average Intensity function in Fiji following generation of a Region of Interest and masking of the DAPI channel to exclude the nucleus when required. In statistical analyses, n = number of embryos or cells measured, and as defined in the figure legend. GraphPad Prism was used for statistical analyses and graph generation. In all statistical tests, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. Tests used are indicated in the associated figure legend and were Student’s t-test, Chi-squared test, Mann–Whitney test, or ANOVA with Bonferroni or Dunn’s post-tests.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con9"><p>Resources</p></fn><fn fn-type="con" id="con10"><p>Resources, Supervision</p></fn><fn fn-type="con" id="con11"><p>Supervision</p></fn><fn fn-type="con" id="con12"><p>Resources, Supervision</p></fn><fn fn-type="con" id="con13"><p>Supervision</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Writing - original draft, Project administration</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Animal experimentation: Fish were housed at the IMCB and the NTU zebrafish facilities under IACUC numbers #140924 and #A18002 respectively, and according to the guidelines of the National Advisory Committee for Laboratory Animal Research. Approval was provided by the Institutional Animal Care and Use Committees of the Biological Resource Centre (IMCB) and NTU according to Agri-Food and Veterinary Authority (AVA) Rules and the National Advisory Committee for Laboratory Animal Research (NACLAR) requirements.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-66596-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Ani</surname> <given-names>B</given-names></name><name><surname>Hewett</surname> <given-names>PW</given-names></name><name><surname>Cudmore</surname> <given-names>MJ</given-names></name><name><surname>Fujisawa</surname> <given-names>T</given-names></name><name><surname>Saifeddine</surname> <given-names>M</given-names></name><name><surname>Williams</surname> <given-names>H</given-names></name><name><surname>Ramma</surname> <given-names>W</given-names></name><name><surname>Sissaoui</surname> <given-names>S</given-names></name><name><surname>Jayaraman</surname> <given-names>PS</given-names></name><name><surname>Ohba</surname> <given-names>M</given-names></name><name><surname>Ahmad</surname> <given-names>S</given-names></name><name><surname>Hollenberg</surname> <given-names>MD</given-names></name><name><surname>Ahmed</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells</article-title><source>Hypertension</source><volume>55</volume><fpage>689</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.109.136333</pub-id><pub-id pub-id-type="pmid">20124108</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname> <given-names>LF</given-names></name><name><surname>Sebolt-Leopold</surname> <given-names>J</given-names></name><name><surname>Meyer</surname> <given-names>MB</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)</article-title><source>Seminars in Oncology</source><volume>30</volume><fpage>105</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2003.08.012</pub-id><pub-id pub-id-type="pmid">14613031</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alli Shaik</surname> <given-names>A</given-names></name><name><surname>Wee</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>RH</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Carney</surname> <given-names>TJ</given-names></name><name><surname>Mathavan</surname> <given-names>S</given-names></name><name><surname>Gunaratne</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Functional mapping of the zebrafish early embryo proteome and transcriptome</article-title><source>Journal of Proteome Research</source><volume>13</volume><fpage>5536</fpage><lpage>5550</lpage><pub-id pub-id-type="doi">10.1021/pr5005136</pub-id><pub-id pub-id-type="pmid">25230361</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anastasaki</surname> <given-names>C</given-names></name><name><surname>Rauen</surname> <given-names>KA</given-names></name><name><surname>Patton</surname> <given-names>EE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish</article-title><source>Disease Models &amp; Mechanisms</source><volume>5</volume><fpage>546</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1242/dmm.008672</pub-id><pub-id pub-id-type="pmid">22301711</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname> <given-names>JL</given-names></name><name><surname>Gesser</surname> <given-names>B</given-names></name><name><surname>Funder</surname> <given-names>ED</given-names></name><name><surname>Nielsen</surname> <given-names>CJF</given-names></name><name><surname>Gotfred-Rasmussen</surname> <given-names>H</given-names></name><name><surname>Rasmussen</surname> <given-names>MK</given-names></name><name><surname>Toth</surname> <given-names>R</given-names></name><name><surname>Gothelf</surname> <given-names>KV</given-names></name><name><surname>Arthur</surname> <given-names>JSC</given-names></name><name><surname>Iversen</surname> <given-names>L</given-names></name><name><surname>Nissen</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4344</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06787-w</pub-id><pub-id pub-id-type="pmid">30341347</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armistead</surname> <given-names>J</given-names></name><name><surname>Hatzold</surname> <given-names>J</given-names></name><name><surname>van Roye</surname> <given-names>A</given-names></name><name><surname>Fahle</surname> <given-names>E</given-names></name><name><surname>Hammerschmidt</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Entosis and apical cell extrusion constitute a tumor-suppressive mechanism downstream of matriptase</article-title><source>Journal of Cell Biology</source><volume>219</volume><elocation-id>e201905190</elocation-id><pub-id pub-id-type="doi">10.1083/jcb.201905190</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Böhm</surname> <given-names>SK</given-names></name><name><surname>Khitin</surname> <given-names>LM</given-names></name><name><surname>Grady</surname> <given-names>EF</given-names></name><name><surname>Aponte</surname> <given-names>G</given-names></name><name><surname>Payan</surname> <given-names>DG</given-names></name><name><surname>Bunnett</surname> <given-names>NW</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Mechanisms of desensitization and resensitization of proteinase-activated receptor-2</article-title><source>Journal of Biological Chemistry</source><volume>271</volume><fpage>22003</fpage><lpage>22016</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.36.22003</pub-id><pub-id pub-id-type="pmid">8703006</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carney</surname> <given-names>TJ</given-names></name><name><surname>von der Hardt</surname> <given-names>S</given-names></name><name><surname>Sonntag</surname> <given-names>C</given-names></name><name><surname>Amsterdam</surname> <given-names>A</given-names></name><name><surname>Topczewski</surname> <given-names>J</given-names></name><name><surname>Hopkins</surname> <given-names>N</given-names></name><name><surname>Hammerschmidt</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Inactivation of serine protease Matriptase1a by its inhibitor Hai1 is required for epithelial integrity of the zebrafish epidermis</article-title><source>Development</source><volume>134</volume><fpage>3461</fpage><lpage>3471</lpage><pub-id pub-id-type="doi">10.1242/dev.004556</pub-id><pub-id pub-id-type="pmid">17728346</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Čáslavský</surname> <given-names>J</given-names></name><name><surname>Klímová</surname> <given-names>Z</given-names></name><name><surname>Vomastek</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ERK and RSK regulate distinct steps of a cellular program that induces transition from multicellular epithelium to single cell phenotype</article-title><source>Cellular Signalling</source><volume>25</volume><fpage>2743</fpage><lpage>2751</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2013.08.024</pub-id><pub-id pub-id-type="pmid">24012955</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Xia</surname> <given-names>L</given-names></name><name><surname>Bruchas</surname> <given-names>MR</given-names></name><name><surname>Solnica-Krezel</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Imaging early embryonic calcium activity with GCaMP6s transgenic zebrafish</article-title><source>Developmental Biology</source><volume>430</volume><fpage>385</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2017.03.010</pub-id><pub-id pub-id-type="pmid">28322738</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname> <given-names>CM</given-names></name><name><surname>Chen</surname> <given-names>YC</given-names></name><name><surname>Su</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>GD</given-names></name><name><surname>Huang</surname> <given-names>KY</given-names></name><name><surname>Lien</surname> <given-names>HW</given-names></name><name><surname>Huang</surname> <given-names>CJ</given-names></name><name><surname>Cheng</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Activation of MEK2 is sufficient to induce skin papilloma formation in transgenic zebrafish</article-title><source>Journal of Biomedical Science</source><volume>22</volume><elocation-id>102</elocation-id><pub-id pub-id-type="doi">10.1186/s12929-015-0207-2</pub-id><pub-id pub-id-type="pmid">26572230</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuderland</surname> <given-names>D</given-names></name><name><surname>Marmor</surname> <given-names>G</given-names></name><name><surname>Shainskaya</surname> <given-names>A</given-names></name><name><surname>Seger</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Calcium-Mediated interactions regulate the subcellular localization of extracellular Signal-Regulated kinases (ERKs)</article-title><source>Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology</source><volume>54</volume><fpage>474</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.33594/000000231</pub-id><pub-id pub-id-type="pmid">32392404</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname> <given-names>H</given-names></name><name><surname>Ramachandran</surname> <given-names>R</given-names></name><name><surname>Hollenberg</surname> <given-names>MD</given-names></name><name><surname>Muruve</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-β receptor signaling pathways contributes to renal fibrosis</article-title><source>Journal of Biological Chemistry</source><volume>288</volume><fpage>37319</fpage><lpage>37331</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.492793</pub-id><pub-id pub-id-type="pmid">24253040</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darmoul</surname> <given-names>D</given-names></name><name><surname>Gratio</surname> <given-names>V</given-names></name><name><surname>Devaud</surname> <given-names>H</given-names></name><name><surname>Laburthe</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Protease-activated receptor 2 in Colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>20927</fpage><lpage>20934</lpage><pub-id pub-id-type="doi">10.1074/jbc.M401430200</pub-id><pub-id pub-id-type="pmid">15010475</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira</surname> <given-names>S</given-names></name><name><surname>López-Muñoz</surname> <given-names>A</given-names></name><name><surname>Candel</surname> <given-names>S</given-names></name><name><surname>Pelegrín</surname> <given-names>P</given-names></name><name><surname>Calado</surname> <given-names>Â</given-names></name><name><surname>Mulero</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>ATP modulates acute inflammation in vivo through dual oxidase 1-derived H2O2 production and NF-κB activation</article-title><source>Journal of Immunology</source><volume>192</volume><fpage>5710</fpage><lpage>5719</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302902</pub-id><pub-id pub-id-type="pmid">24842759</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enyedi</surname> <given-names>B</given-names></name><name><surname>Niethammer</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mechanisms of epithelial wound detection</article-title><source>Trends in Cell Biology</source><volume>25</volume><fpage>398</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2015.02.007</pub-id><pub-id pub-id-type="pmid">25813429</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favata</surname> <given-names>MF</given-names></name><name><surname>Horiuchi</surname> <given-names>KY</given-names></name><name><surname>Manos</surname> <given-names>EJ</given-names></name><name><surname>Daulerio</surname> <given-names>AJ</given-names></name><name><surname>Stradley</surname> <given-names>DA</given-names></name><name><surname>Feeser</surname> <given-names>WS</given-names></name><name><surname>Van Dyk</surname> <given-names>DE</given-names></name><name><surname>Pitts</surname> <given-names>WJ</given-names></name><name><surname>Earl</surname> <given-names>RA</given-names></name><name><surname>Hobbs</surname> <given-names>F</given-names></name><name><surname>Copeland</surname> <given-names>RA</given-names></name><name><surname>Magolda</surname> <given-names>RL</given-names></name><name><surname>Scherle</surname> <given-names>PA</given-names></name><name><surname>Trzaskos</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Identification of a novel inhibitor of mitogen-activated protein kinase kinase</article-title><source>Journal of Biological Chemistry</source><volume>273</volume><fpage>18623</fpage><lpage>18632</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.29.18623</pub-id><pub-id pub-id-type="pmid">9660836</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>Y</given-names></name><name><surname>Santoriello</surname> <given-names>C</given-names></name><name><surname>Mione</surname> <given-names>M</given-names></name><name><surname>Hurlstone</surname> <given-names>A</given-names></name><name><surname>Martin</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Live imaging of innate immune cell sensing of transformed cells in zebrafish larvae: parallels between tumor initiation and wound inflammation</article-title><source>PLOS Biology</source><volume>8</volume><elocation-id>e1000562</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000562</pub-id><pub-id pub-id-type="pmid">21179501</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gault</surname> <given-names>WJ</given-names></name><name><surname>Enyedi</surname> <given-names>B</given-names></name><name><surname>Niethammer</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Osmotic surveillance mediates rapid wound closure through nucleotide release</article-title><source>Journal of Cell Biology</source><volume>207</volume><fpage>767</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1083/jcb.201408049</pub-id><pub-id pub-id-type="pmid">25533845</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gawecka</surname> <given-names>JE</given-names></name><name><surname>Young-Robbins</surname> <given-names>SS</given-names></name><name><surname>Sulzmaier</surname> <given-names>FJ</given-names></name><name><surname>Caliva</surname> <given-names>MJ</given-names></name><name><surname>Heikkilä</surname> <given-names>MM</given-names></name><name><surname>Matter</surname> <given-names>ML</given-names></name><name><surname>Ramos</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>RSK2 protein suppresses integrin activation and fibronectin matrix assembly and promotes cell migration</article-title><source>Journal of Biological Chemistry</source><volume>287</volume><fpage>43424</fpage><lpage>43437</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.423046</pub-id><pub-id pub-id-type="pmid">23118220</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goon Goh</surname> <given-names>F</given-names></name><name><surname>Sloss</surname> <given-names>CM</given-names></name><name><surname>Cunningham</surname> <given-names>MR</given-names></name><name><surname>Nilsson</surname> <given-names>M</given-names></name><name><surname>Cadalbert</surname> <given-names>L</given-names></name><name><surname>Plevin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>G-protein-dependent and -independent pathways regulate proteinase-activated receptor-2 mediated p65 NFkappaB serine 536 phosphorylation in human keratinocytes</article-title><source>Cellular Signalling</source><volume>20</volume><fpage>1267</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2008.02.015</pub-id><pub-id pub-id-type="pmid">18424071</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatzold</surname> <given-names>J</given-names></name><name><surname>Beleggia</surname> <given-names>F</given-names></name><name><surname>Herzig</surname> <given-names>H</given-names></name><name><surname>Altmüller</surname> <given-names>J</given-names></name><name><surname>Nürnberg</surname> <given-names>P</given-names></name><name><surname>Bloch</surname> <given-names>W</given-names></name><name><surname>Wollnik</surname> <given-names>B</given-names></name><name><surname>Hammerschmidt</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tumor suppression in basal keratinocytes via dual non-cell-autonomous functions of a Na,K-ATPase beta subunit</article-title><source>eLife</source><volume>5</volume><elocation-id>e14277</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.14277</pub-id><pub-id pub-id-type="pmid">27240166</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Bailly</surname> <given-names>MA</given-names></name><name><surname>Panetti</surname> <given-names>TS</given-names></name><name><surname>Cappello</surname> <given-names>M</given-names></name><name><surname>Konigsberg</surname> <given-names>WH</given-names></name><name><surname>Bromberg</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Formation of tissue factor-factor VIIa-factor xa complex promotes cellular signaling and migration of human breast Cancer cells</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>2</volume><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2004.00545.x</pub-id><pub-id pub-id-type="pmid">14717972</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>S</given-names></name><name><surname>Elf</surname> <given-names>S</given-names></name><name><surname>Lythgoe</surname> <given-names>K</given-names></name><name><surname>Hitosugi</surname> <given-names>T</given-names></name><name><surname>Taunton</surname> <given-names>J</given-names></name><name><surname>Zhou</surname> <given-names>W</given-names></name><name><surname>Xiong</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Muller</surname> <given-names>S</given-names></name><name><surname>Fan</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>SY</given-names></name><name><surname>Gu</surname> <given-names>TL</given-names></name><name><surname>Chen</surname> <given-names>ZG</given-names></name><name><surname>Shin</surname> <given-names>DM</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells</article-title><source>Journal of Clinical Investigation</source><volume>120</volume><fpage>1165</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1172/JCI40582</pub-id><pub-id pub-id-type="pmid">20234090</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanke</surname> <given-names>T</given-names></name><name><surname>Macfarlane</surname> <given-names>SR</given-names></name><name><surname>Seatter</surname> <given-names>MJ</given-names></name><name><surname>Davenport</surname> <given-names>E</given-names></name><name><surname>Paul</surname> <given-names>A</given-names></name><name><surname>McKenzie</surname> <given-names>RC</given-names></name><name><surname>Plevin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Proteinase-activated receptor-2-mediated activation of stress-activated protein kinases and inhibitory kappa B kinases in NCTC 2544 keratinocytes</article-title><source>Journal of Biological Chemistry</source><volume>276</volume><fpage>31657</fpage><lpage>31666</lpage><pub-id pub-id-type="doi">10.1074/jbc.M100377200</pub-id><pub-id pub-id-type="pmid">11413129</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanther</surname> <given-names>M</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Mühlbauer</surname> <given-names>M</given-names></name><name><surname>Mackey</surname> <given-names>LC</given-names></name><name><surname>Flynn</surname> <given-names>EJ</given-names></name><name><surname>Bagnat</surname> <given-names>M</given-names></name><name><surname>Jobin</surname> <given-names>C</given-names></name><name><surname>Rawls</surname> <given-names>JF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Microbial colonization induces dynamic temporal and spatial patterns of NF-κB activation in the zebrafish digestive tract</article-title><source>Gastroenterology</source><volume>141</volume><fpage>197</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.03.042</pub-id><pub-id pub-id-type="pmid">21439961</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawaguchi</surname> <given-names>M</given-names></name><name><surname>Takeda</surname> <given-names>N</given-names></name><name><surname>Hoshiko</surname> <given-names>S</given-names></name><name><surname>Yorita</surname> <given-names>K</given-names></name><name><surname>Baba</surname> <given-names>T</given-names></name><name><surname>Sawaguchi</surname> <given-names>A</given-names></name><name><surname>Nezu</surname> <given-names>Y</given-names></name><name><surname>Yoshikawa</surname> <given-names>T</given-names></name><name><surname>Fukushima</surname> <given-names>T</given-names></name><name><surname>Kataoka</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Membrane-bound serine protease inhibitor HAI-1 is required for maintenance of intestinal epithelial integrity</article-title><source>The American Journal of Pathology</source><volume>179</volume><fpage>1815</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2011.06.038</pub-id><pub-id pub-id-type="pmid">21840293</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimmel</surname> <given-names>CB</given-names></name><name><surname>Ballard</surname> <given-names>WW</given-names></name><name><surname>Kimmel</surname> <given-names>SR</given-names></name><name><surname>Ullmann</surname> <given-names>B</given-names></name><name><surname>Schilling</surname> <given-names>TF</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Stages of embryonic development of the zebrafish</article-title><source>Developmental Dynamics</source><volume>203</volume><fpage>253</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1002/aja.1002030302</pub-id><pub-id pub-id-type="pmid">8589427</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>RT</given-names></name><name><surname>Asharani</surname> <given-names>PV</given-names></name><name><surname>Carney</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Basal keratinocytes contribute to all strata of the adult zebrafish epidermis</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e84858</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0084858</pub-id><pub-id pub-id-type="pmid">24400120</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>Q</given-names></name><name><surname>Low</surname> <given-names>LWL</given-names></name><name><surname>Lau</surname> <given-names>A</given-names></name><name><surname>Chua</surname> <given-names>EWL</given-names></name><name><surname>Matsuoka</surname> <given-names>Y</given-names></name><name><surname>Lian</surname> <given-names>Y</given-names></name><name><surname>Monteiro</surname> <given-names>A</given-names></name><name><surname>Tate</surname> <given-names>S</given-names></name><name><surname>Gunaratne</surname> <given-names>J</given-names></name><name><surname>Carney</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tracking genome-editing and associated molecular perturbations by SWATH mass spectrometry</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>15240</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-51612-z</pub-id><pub-id pub-id-type="pmid">31645615</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>List</surname> <given-names>K</given-names></name><name><surname>Szabo</surname> <given-names>R</given-names></name><name><surname>Molinolo</surname> <given-names>A</given-names></name><name><surname>Sriuranpong</surname> <given-names>V</given-names></name><name><surname>Redeye</surname> <given-names>V</given-names></name><name><surname>Murdock</surname> <given-names>T</given-names></name><name><surname>Burke</surname> <given-names>B</given-names></name><name><surname>Nielsen</surname> <given-names>BS</given-names></name><name><surname>Gutkind</surname> <given-names>JS</given-names></name><name><surname>Bugge</surname> <given-names>TH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation</article-title><source>Genes &amp; Development</source><volume>19</volume><fpage>1934</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.1101/gad.1300705</pub-id><pub-id pub-id-type="pmid">16103220</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macfarlane</surname> <given-names>SR</given-names></name><name><surname>Sloss</surname> <given-names>CM</given-names></name><name><surname>Cameron</surname> <given-names>P</given-names></name><name><surname>Kanke</surname> <given-names>T</given-names></name><name><surname>McKenzie</surname> <given-names>RC</given-names></name><name><surname>Plevin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The role of intracellular Ca2+ in the regulation of proteinase-activated receptor-2 mediated nuclear factor kappa B signalling in keratinocytes</article-title><source>British Journal of Pharmacology</source><volume>145</volume><fpage>535</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706204</pub-id><pub-id pub-id-type="pmid">15821758</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname> <given-names>H</given-names></name><name><surname>Fukuyasu</surname> <given-names>Y</given-names></name><name><surname>Yoshida</surname> <given-names>S</given-names></name><name><surname>Fukuda</surname> <given-names>M</given-names></name><name><surname>Saeki</surname> <given-names>K</given-names></name><name><surname>Matsuno</surname> <given-names>H</given-names></name><name><surname>Yamauchi</surname> <given-names>Y</given-names></name><name><surname>Yoshida</surname> <given-names>K</given-names></name><name><surname>Hirata</surname> <given-names>K</given-names></name><name><surname>Miyamoto</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Fluorescent probes for hydrogen peroxide based on a non-oxidative mechanism</article-title><source>Angewandte Chemie International Edition</source><volume>43</volume><fpage>2389</fpage><lpage>2391</lpage><pub-id pub-id-type="doi">10.1002/anie.200452381</pub-id><pub-id pub-id-type="pmid">15114569</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>CE</given-names></name><name><surname>List</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cell surface-anchored serine proteases in Cancer progression and metastasis</article-title><source>Cancer and Metastasis Reviews</source><volume>38</volume><fpage>357</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1007/s10555-019-09811-7</pub-id><pub-id pub-id-type="pmid">31529338</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathias</surname> <given-names>JR</given-names></name><name><surname>Dodd</surname> <given-names>ME</given-names></name><name><surname>Walters</surname> <given-names>KB</given-names></name><name><surname>Rhodes</surname> <given-names>J</given-names></name><name><surname>Kanki</surname> <given-names>JP</given-names></name><name><surname>Look</surname> <given-names>AT</given-names></name><name><surname>Huttenlocher</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Live imaging of chronic inflammation caused by mutation of zebrafish Hai1</article-title><source>Journal of Cell Science</source><volume>120</volume><fpage>3372</fpage><lpage>3383</lpage><pub-id pub-id-type="doi">10.1242/jcs.009159</pub-id><pub-id pub-id-type="pmid">17881499</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname> <given-names>KL</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Hepler</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology</article-title><source>Molecular Pharmacology</source><volume>77</volume><fpage>1005</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1124/mol.109.062018</pub-id><pub-id pub-id-type="pmid">20215560</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Méant</surname> <given-names>A</given-names></name><name><surname>Gao</surname> <given-names>B</given-names></name><name><surname>Lavoie</surname> <given-names>G</given-names></name><name><surname>Nourreddine</surname> <given-names>S</given-names></name><name><surname>Jung</surname> <given-names>F</given-names></name><name><surname>Aubert</surname> <given-names>L</given-names></name><name><surname>Tcherkezian</surname> <given-names>J</given-names></name><name><surname>Gingras</surname> <given-names>AC</given-names></name><name><surname>Roux</surname> <given-names>PP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Proteomic analysis reveals a role for RSK in p120-catenin phosphorylation and melanoma Cell-Cell adhesion</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>19</volume><fpage>50</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1074/mcp.RA119.001811</pub-id><pub-id pub-id-type="pmid">31678930</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname> <given-names>DR</given-names></name><name><surname>Ding</surname> <given-names>Y</given-names></name><name><surname>Ricks</surname> <given-names>TK</given-names></name><name><surname>Gullapalli</surname> <given-names>A</given-names></name><name><surname>Wolfe</surname> <given-names>BL</given-names></name><name><surname>Trejo</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Protease-Activated Receptor-2 is essential for factor VIIa and Xa–Induced Signaling, Migration, and Invasion of Breast Cancer Cells</article-title><source>Cancer Research</source><volume>66</volume><fpage>307</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1735</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagaike</surname> <given-names>K</given-names></name><name><surname>Kawaguchi</surname> <given-names>M</given-names></name><name><surname>Takeda</surname> <given-names>N</given-names></name><name><surname>Fukushima</surname> <given-names>T</given-names></name><name><surname>Sawaguchi</surname> <given-names>A</given-names></name><name><surname>Kohama</surname> <given-names>K</given-names></name><name><surname>Setoyama</surname> <given-names>M</given-names></name><name><surname>Kataoka</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Defect of hepatocyte growth factor activator inhibitor type 1/serine protease inhibitor, Kunitz type 1 (Hai-1/Spint1) leads to ichthyosis-like condition and abnormal hair development in mice</article-title><source>The American Journal of Pathology</source><volume>173</volume><fpage>1464</fpage><lpage>1475</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2008.071142</pub-id><pub-id pub-id-type="pmid">18832587</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niethammer</surname> <given-names>P</given-names></name><name><surname>Grabher</surname> <given-names>C</given-names></name><name><surname>Look</surname> <given-names>AT</given-names></name><name><surname>Mitchison</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish</article-title><source>Nature</source><volume>459</volume><fpage>996</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1038/nature08119</pub-id><pub-id pub-id-type="pmid">19494811</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rattenholl</surname> <given-names>A</given-names></name><name><surname>Seeliger</surname> <given-names>S</given-names></name><name><surname>Buddenkotte</surname> <given-names>J</given-names></name><name><surname>Schön</surname> <given-names>M</given-names></name><name><surname>Schön</surname> <given-names>MP</given-names></name><name><surname>Ständer</surname> <given-names>S</given-names></name><name><surname>Vergnolle</surname> <given-names>N</given-names></name><name><surname>Steinhoff</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Proteinase-activated receptor-2 (PAR2): a tumor suppressor in skin carcinogenesis</article-title><source>Journal of Investigative Dermatology</source><volume>127</volume><fpage>2245</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5700847</pub-id><pub-id pub-id-type="pmid">17476297</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razzell</surname> <given-names>W</given-names></name><name><surname>Evans</surname> <given-names>IR</given-names></name><name><surname>Martin</surname> <given-names>P</given-names></name><name><surname>Wood</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Calcium flashes orchestrate the wound inflammatory response through DUOX activation and hydrogen peroxide release</article-title><source>Current Biology</source><volume>23</volume><fpage>424</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2013.01.058</pub-id><pub-id pub-id-type="pmid">23394834</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redd</surname> <given-names>MJ</given-names></name><name><surname>Kelly</surname> <given-names>G</given-names></name><name><surname>Dunn</surname> <given-names>G</given-names></name><name><surname>Way</surname> <given-names>M</given-names></name><name><surname>Martin</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Imaging macrophage chemotaxis in vivo: studies of microtubule function in zebrafish wound inflammation</article-title><source>Cell Motility and the Cytoskeleton</source><volume>63</volume><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1002/cm.20133</pub-id><pub-id pub-id-type="pmid">16671106</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renshaw</surname> <given-names>SA</given-names></name><name><surname>Loynes</surname> <given-names>CA</given-names></name><name><surname>Trushell</surname> <given-names>DM</given-names></name><name><surname>Elworthy</surname> <given-names>S</given-names></name><name><surname>Ingham</surname> <given-names>PW</given-names></name><name><surname>Whyte</surname> <given-names>MK</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A transgenic zebrafish model of neutrophilic inflammation</article-title><source>Blood</source><volume>108</volume><fpage>3976</fpage><lpage>3978</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-05-024075</pub-id><pub-id pub-id-type="pmid">16926288</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigutto</surname> <given-names>S</given-names></name><name><surname>Hoste</surname> <given-names>C</given-names></name><name><surname>Grasberger</surname> <given-names>H</given-names></name><name><surname>Milenkovic</surname> <given-names>M</given-names></name><name><surname>Communi</surname> <given-names>D</given-names></name><name><surname>Dumont</surname> <given-names>JE</given-names></name><name><surname>Corvilain</surname> <given-names>B</given-names></name><name><surname>Miot</surname> <given-names>F</given-names></name><name><surname>De</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Activation of dual oxidases Duox1 and Duox2: differential regulation mediated by camp-dependent protein kinase and protein kinase C-dependent phosphorylation</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>6725</fpage><lpage>6734</lpage><pub-id pub-id-type="doi">10.1074/jbc.M806893200</pub-id><pub-id pub-id-type="pmid">19144650</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romeo</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Roux</surname> <given-names>PP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regulation and function of the RSK family of protein kinases</article-title><source>Biochemical Journal</source><volume>441</volume><fpage>553</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1042/BJ20110289</pub-id><pub-id pub-id-type="pmid">22187936</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothwarf</surname> <given-names>DM</given-names></name><name><surname>Zandi</surname> <given-names>E</given-names></name><name><surname>Natoli</surname> <given-names>G</given-names></name><name><surname>Karin</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex</article-title><source>Nature</source><volume>395</volume><fpage>297</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1038/26261</pub-id><pub-id pub-id-type="pmid">9751060</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sales</surname> <given-names>KU</given-names></name><name><surname>Friis</surname> <given-names>S</given-names></name><name><surname>Konkel</surname> <given-names>JE</given-names></name><name><surname>Godiksen</surname> <given-names>S</given-names></name><name><surname>Hatakeyama</surname> <given-names>M</given-names></name><name><surname>Hansen</surname> <given-names>KK</given-names></name><name><surname>Rogatto</surname> <given-names>SR</given-names></name><name><surname>Szabo</surname> <given-names>R</given-names></name><name><surname>Vogel</surname> <given-names>LK</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Gutkind</surname> <given-names>JS</given-names></name><name><surname>Bugge</surname> <given-names>TH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis</article-title><source>Oncogene</source><volume>34</volume><fpage>346</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.563</pub-id><pub-id pub-id-type="pmid">24469043</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salhi</surname> <given-names>A</given-names></name><name><surname>Farhadian</surname> <given-names>JA</given-names></name><name><surname>Giles</surname> <given-names>KM</given-names></name><name><surname>Vega-Saenz de Miera</surname> <given-names>E</given-names></name><name><surname>Silva</surname> <given-names>IP</given-names></name><name><surname>Bourque</surname> <given-names>C</given-names></name><name><surname>Yeh</surname> <given-names>K</given-names></name><name><surname>Chhangawala</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Ye</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>DY</given-names></name><name><surname>Hernando-Monge</surname> <given-names>E</given-names></name><name><surname>Houvras</surname> <given-names>Y</given-names></name><name><surname>Osman</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RSK1 activation promotes invasion in nodular melanoma</article-title><source>The American Journal of Pathology</source><volume>185</volume><fpage>704</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2014.11.021</pub-id><pub-id pub-id-type="pmid">25579842</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapkota</surname> <given-names>GP</given-names></name><name><surname>Cummings</surname> <given-names>L</given-names></name><name><surname>Newell</surname> <given-names>FS</given-names></name><name><surname>Armstrong</surname> <given-names>C</given-names></name><name><surname>Bain</surname> <given-names>J</given-names></name><name><surname>Frodin</surname> <given-names>M</given-names></name><name><surname>Grauert</surname> <given-names>M</given-names></name><name><surname>Hoffmann</surname> <given-names>M</given-names></name><name><surname>Schnapp</surname> <given-names>G</given-names></name><name><surname>Steegmaier</surname> <given-names>M</given-names></name><name><surname>Cohen</surname> <given-names>P</given-names></name><name><surname>Alessi</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo</article-title><source>Biochemical Journal</source><volume>401</volume><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1042/BJ20061088</pub-id><pub-id pub-id-type="pmid">17040210</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schäfer</surname> <given-names>M</given-names></name><name><surname>Werner</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cancer as an overhealing wound: an old hypothesis revisited</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>9</volume><fpage>628</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1038/nrm2455</pub-id><pub-id pub-id-type="pmid">18628784</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schechter</surname> <given-names>NM</given-names></name><name><surname>Brass</surname> <given-names>LF</given-names></name><name><surname>Lavker</surname> <given-names>RM</given-names></name><name><surname>Jensen</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Reaction of mast cell proteases tryptase and chymase with protease activated receptors (PARs) on keratinocytes and fibroblasts</article-title><source>Journal of Cellular Physiology</source><volume>176</volume><fpage>365</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4652(199808)176:2&lt;365::AID-JCP15&gt;3.0.CO;2-2</pub-id><pub-id pub-id-type="pmid">9648924</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schepis</surname> <given-names>A</given-names></name><name><surname>Barker</surname> <given-names>A</given-names></name><name><surname>Srinivasan</surname> <given-names>Y</given-names></name><name><surname>Balouch</surname> <given-names>E</given-names></name><name><surname>Zheng</surname> <given-names>Y</given-names></name><name><surname>Lam</surname> <given-names>I</given-names></name><name><surname>Clay</surname> <given-names>H</given-names></name><name><surname>Hsiao</surname> <given-names>CD</given-names></name><name><surname>Coughlin</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Protease signaling regulates apical cell extrusion, cell contacts, and proliferation in epithelia</article-title><source>Journal of Cell Biology</source><volume>217</volume><fpage>1097</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1083/jcb.201709118</pub-id><pub-id pub-id-type="pmid">29301867</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreck</surname> <given-names>R</given-names></name><name><surname>Rieber</surname> <given-names>P</given-names></name><name><surname>Baeuerle</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1</article-title><source>The EMBO Journal</source><volume>10</volume><fpage>2247</fpage><lpage>2258</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1991.tb07761.x</pub-id><pub-id pub-id-type="pmid">2065663</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname> <given-names>J</given-names></name><name><surname>Deng</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>N</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Dai</surname> <given-names>E</given-names></name><name><surname>Deng</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PAR-2 promotes invasion and migration of esophageal Cancer cells by activating MEK/ERK and PI3K/Akt signaling pathway</article-title><source>International Journal of Clinical and Experimental Pathology</source><volume>12</volume><fpage>787</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">31933886</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>K</given-names></name><name><surname>Queiroz</surname> <given-names>KC</given-names></name><name><surname>Stap</surname> <given-names>J</given-names></name><name><surname>Richel</surname> <given-names>DJ</given-names></name><name><surname>Spek</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Protease-activated receptor-2 induces migration of pancreatic Cancer cells in an extracellular ATP-dependent manner</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>11</volume><fpage>1892</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1111/jth.12361</pub-id><pub-id pub-id-type="pmid">23899344</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>GX</given-names></name><name><surname>Yang</surname> <given-names>WS</given-names></name><name><surname>Jin</surname> <given-names>L</given-names></name><name><surname>Matter</surname> <given-names>ML</given-names></name><name><surname>Ramos</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>RSK2 drives cell motility by serine phosphorylation of LARG and activation of rho GTPases</article-title><source>PNAS</source><volume>115</volume><fpage>E190</fpage><lpage>E199</lpage><pub-id pub-id-type="doi">10.1073/pnas.1708584115</pub-id><pub-id pub-id-type="pmid">29279389</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivak</surname> <given-names>JM</given-names></name><name><surname>Petersen</surname> <given-names>LF</given-names></name><name><surname>Amaya</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>FGF signal interpretation is directed by sprouty and spred proteins during mesoderm formation</article-title><source>Developmental Cell</source><volume>8</volume><fpage>689</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2005.02.011</pub-id><pub-id pub-id-type="pmid">15866160</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulzmaier</surname> <given-names>FJ</given-names></name><name><surname>Young-Robbins</surname> <given-names>S</given-names></name><name><surname>Jiang</surname> <given-names>P</given-names></name><name><surname>Geerts</surname> <given-names>D</given-names></name><name><surname>Prechtl</surname> <given-names>AM</given-names></name><name><surname>Matter</surname> <given-names>ML</given-names></name><name><surname>Kesari</surname> <given-names>S</given-names></name><name><surname>Ramos</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics</article-title><source>Oncotarget</source><volume>7</volume><fpage>79869</fpage><lpage>79884</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.13084</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname> <given-names>R</given-names></name><name><surname>Molinolo</surname> <given-names>A</given-names></name><name><surname>List</surname> <given-names>K</given-names></name><name><surname>Bugge</surname> <given-names>TH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development</article-title><source>Oncogene</source><volume>26</volume><fpage>1546</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209966</pub-id><pub-id pub-id-type="pmid">16983341</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname> <given-names>R</given-names></name><name><surname>Rasmussen</surname> <given-names>AL</given-names></name><name><surname>Moyer</surname> <given-names>AB</given-names></name><name><surname>Kosa</surname> <given-names>P</given-names></name><name><surname>Schafer</surname> <given-names>JM</given-names></name><name><surname>Molinolo</surname> <given-names>AA</given-names></name><name><surname>Gutkind</surname> <given-names>JS</given-names></name><name><surname>Bugge</surname> <given-names>TH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase</article-title><source>Oncogene</source><volume>30</volume><fpage>2003</fpage><lpage>2016</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.586</pub-id><pub-id pub-id-type="pmid">21217780</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname> <given-names>Y</given-names></name><name><surname>Sekiguchi</surname> <given-names>F</given-names></name><name><surname>Hong</surname> <given-names>H</given-names></name><name><surname>Kawabata</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>PAR2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells</article-title><source>Biochemical and Biophysical Research Communications</source><volume>377</volume><fpage>622</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.10.018</pub-id><pub-id pub-id-type="pmid">18854173</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanimura</surname> <given-names>S</given-names></name><name><surname>Takeda</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ERK signalling as a regulator of cell motility</article-title><source>The Journal of Biochemistry</source><volume>162</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1093/jb/mvx048</pub-id><pub-id pub-id-type="pmid">28903547</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thisse</surname> <given-names>C</given-names></name><name><surname>Thisse</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>High-resolution in situ hybridization to whole-mount zebrafish embryos</article-title><source>Nature Protocols</source><volume>3</volume><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.514</pub-id><pub-id pub-id-type="pmid">18193022</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turvey</surname> <given-names>SE</given-names></name><name><surname>Durandy</surname> <given-names>A</given-names></name><name><surname>Fischer</surname> <given-names>A</given-names></name><name><surname>Fung</surname> <given-names>SY</given-names></name><name><surname>Geha</surname> <given-names>RS</given-names></name><name><surname>Gewies</surname> <given-names>A</given-names></name><name><surname>Giese</surname> <given-names>T</given-names></name><name><surname>Greil</surname> <given-names>J</given-names></name><name><surname>Keller</surname> <given-names>B</given-names></name><name><surname>McKinnon</surname> <given-names>ML</given-names></name><name><surname>Neven</surname> <given-names>B</given-names></name><name><surname>Rozmus</surname> <given-names>J</given-names></name><name><surname>Ruland</surname> <given-names>J</given-names></name><name><surname>Snow</surname> <given-names>AL</given-names></name><name><surname>Stepensky</surname> <given-names>P</given-names></name><name><surname>Warnatz</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The CARD11-BCL10-MALT1 (CBM) signalosome complex: stepping into the limelight of human primary immunodeficiency</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>134</volume><fpage>276</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2014.06.015</pub-id><pub-id pub-id-type="pmid">25087226</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Merwe</surname> <given-names>JQ</given-names></name><name><surname>Moreau</surname> <given-names>F</given-names></name><name><surname>MacNaughton</surname> <given-names>WK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Protease-activated receptor-2 stimulates intestinal epithelial chloride transport through activation of PLC and selective PKC isoforms</article-title><source>American Journal of Physiology-Gastrointestinal and Liver Physiology</source><volume>296</volume><fpage>G1258</fpage><lpage>G1266</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.90425.2008</pub-id><pub-id pub-id-type="pmid">19359428</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Eeden</surname> <given-names>FJ</given-names></name><name><surname>Granato</surname> <given-names>M</given-names></name><name><surname>Schach</surname> <given-names>U</given-names></name><name><surname>Brand</surname> <given-names>M</given-names></name><name><surname>Furutani-Seiki</surname> <given-names>M</given-names></name><name><surname>Haffter</surname> <given-names>P</given-names></name><name><surname>Hammerschmidt</surname> <given-names>M</given-names></name><name><surname>Heisenberg</surname> <given-names>CP</given-names></name><name><surname>Jiang</surname> <given-names>YJ</given-names></name><name><surname>Kane</surname> <given-names>DA</given-names></name><name><surname>Kelsh</surname> <given-names>RN</given-names></name><name><surname>Mullins</surname> <given-names>MC</given-names></name><name><surname>Odenthal</surname> <given-names>J</given-names></name><name><surname>Warga</surname> <given-names>RM</given-names></name><name><surname>Nüsslein-Volhard</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Genetic analysis of fin formation in the zebrafish, <italic>Danio rerio</italic></article-title><source>Development</source><volume>123</volume><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1242/dev.123.1.255</pub-id><pub-id pub-id-type="pmid">9007245</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>DeFea</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Protease-activated receptor-2 simultaneously directs beta-arrestin-1-dependent inhibition and Galphaq-dependent activation of phosphatidylinositol 3-kinase</article-title><source>Biochemistry</source><volume>45</volume><fpage>9374</fpage><lpage>9385</lpage><pub-id pub-id-type="doi">10.1021/bi0602617</pub-id><pub-id pub-id-type="pmid">16878972</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>P</given-names></name><name><surname>Metcalf</surname> <given-names>M</given-names></name><name><surname>Bunnett</surname> <given-names>NW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Biased signaling of Protease-Activated receptors</article-title><source>Frontiers in Endocrinology</source><volume>5</volume><elocation-id>67</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2014.00067</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66596.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Reviewing Editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Rosenblatt</surname><given-names>Jody</given-names> </name><role>Reviewer</role><aff><institution>King's College London</institution><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.01.21.427549">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.01.21.427549v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This manuscript unravels a detailed bipartite signaling mechanism, activation of which results in epithelial inflammation and cell motility. The paper is potentially of broad interest to cancer biologists and epithelial cell biologists. The data generated using the combination of genetic analyses, chemical inhibitors, and state-of-the-art confocal microscopy is of exceptionally high quality and supports the majority of the claims made in this paper.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Matriptase generates a tissue damage response via promoting Gq signalling, leading to RSK and DUOX activation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Jody Rosenblatt as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Jonathan Cooper as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential Revisions:</p><p>Having conferred, we all agree that the paper is of interest and very thoroughly done regarding most aspects of the paper. The main things we would like you to address are the following:</p><p>1. Test whether the inflammatory response is a downstream consequence of poor epithelial barrier function, due to the primary epidermal phenotype. This seems to bear out in your experiments but could be addressed with dextran permeability or other approaches.</p><p>2. Address if the cell motility phenotype really lies downstream of DAG or is in a parallel pathway.</p><p>3. The paper is generally well-written but quite long. Please consider editing for conciseness and brevity.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. Are the epithelial cells really more motile or is the primary cause that they no longer act collectively together like an epithelium, and migrate because of this?</p><p>2. You mention a comprehensive proteomic screen yet there is no real reference to this in how you went about it in your experiments. Were the proteomics results, in fact, used? The rationale seems to go without it. If not, do you need to include it?</p><p>3. Your analysis frequently depends on inhibitors. While you explain that sometimes morphants didn't work, I think you need to at least change the language in your results to suggest, as you could be having some off-target effects with drugs like U0126 and others.</p><p>4. Throughout, I found that the paper was logically ordered, and the results were very clear. However, I did find that the introduction and the discussion of the pathway could be more concise and clearer. It may be useful here to use a schematic to show the pathway implied before and then how your findings changed that, which could go at the beginning of the paper so people know where you are going.</p><p>5. Throughout, you mention the n in the figure legends but don't refer to what the n is-is it total embryos used for each condition or experimental numbers?</p><p>6. What are the differences between ERK activation in nucleus and cytoplasm?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. It is important to directly link the hai1-matriptase system to DAG to implicate that arm of the signaling cascade. Is it possible for the authors to show the elevated levels of DAG in the hai1 mutant or to inhibit DAG in the hai1 mutant background by chemical or genetic means?</p><p>2. To support their conclusion that the two arms of the signaling cascade are causally linked with the phenotypic manifestation, the increase in H2O2 levels, Ca++ flashes, the activation of NfkB signaling, nuclear localization of phosphoRSK need to be shown just before the phenotype arise, if not for all at least for pRSK and NFkB activation. It would also be pertinent to block the signaling arms (using inhibitors) before the phenotypic onset and after the phenotype sets in to delineate the requirement of the cascade for phenotypic manifestation versus phenotypic maintenance.</p><p>3. Given that the Hai1-Matriptase system activates this bipartite signaling cascade to control the inflammation and epithelial cell motility, it is intriguing that the hai1 alleles are viable. How do authors explain the resolution of phenotype and survival of animals to adulthood? This aspect must be discussed.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>The main problem with this manuscript lies not with the experimental data but instead with the way it is presented. The manuscript is far too long and the figures too numerous. Much of the data could be removed or moved to supplementary and the paper should be condensed down to five or six figures.</p><p>As indicated above, a major concern is that the relevance of these findings to a tissue damage response – which is openly stated in the manuscript's title – are not clear or at least not clearly supported by the data. The title of the paper is misleading as the authors don't show any real evidence that this is a true tissue damage response or show any data on how matriptase is activated (or Hai1a might be inactivated) downstream of damage/wounding. Overexpression of matriptase (or inactivation of Hai1a) leads to many of the same biological outcomes as wounding but claiming this is a tissue damage response without directly linking it to damage is a step too far and unnecessary. This message should be toned down throughout the manuscript and the title should be changed. Despite the manuscript being overly long, in multiple instances, the authors fail to adequately discuss the broader meaning of their findings, The discussion is far too long and reads more like a literature review rather than an attempt to extend their discoveries to other systems or contexts. The authors need to be much more concise throughout. If the authors can fix these problems with the structure and presentation of the paper as well as address the comments below then I would support publication.</p><p>1. To this reviewer, the authors did not clearly characterise the &quot;inflammatory phenotype&quot;, nor explain the relevance of the &quot;epidermal phenotype&quot; for the fully-formed organism. As a criticism to the conclusion that neutrophils are highly migratory in Hai1a mutants, in comparison to WT, has it been considered that the increase in cell speed could be due to the lack of spatial constraint (which is instead present in WT, since neutrophils are moving within the vasculature?). Furthermore, is the lack of directionality (figure 1D) a real surprise, or a mere consequence of the lack of imposed stimuli (e.g. a wound) in these settings?</p><p>2. &quot;We noted that again, whilst there was brief local recruitment in the mutant, more distant neutrophils appeared apathetic to the wound and remained migrating randomly, unlike in wild-type where neutrophils were recruited from a great distance and tracked to the wound with high directionality&quot;. The distance traveled by neutrophils cannot be appreciated from figures 1F-G.</p><p>3. Using the stain pentafluorobenzenesulfonyl fluorescein (PFBSF) (Maeda et al., 2004), we observed significantly higher levels of H2O2 in the trunk and tails of hai1a mutants at 24 and 48hpf (Figure 1G-I, Figure S1G-H). These figure references are misplaced.</p><p>4. In figure 4, the authors demonstrate that Hai1a mutants have hyperactivation of the NFkB signalling (Figure 4B), and that this is due to H2O2, as it can be rescued by treatment with a DUOX morpholino (Figure 4K). Strangely however, they also found that inhibition of calcium flashes via 2-APB only very moderately ameliorates the NFkB overactivation (Figure S4F-G). If DUOX is activated by Calcium, shouldn't the two treatments (DUOX morpholino and 2-APB treatment) yield the same response? How do the authors explain this observation, and fit it within their working model?</p><p>5. The authors briefly mention that in a subset of cells (TP63 +ve cells), pERK was observed both in the nucleus and cytosol, while in another subset of cells (peridermal cells) it was only observed in the nucleus. As in other instances throughout the manuscript, the authors fail to further comment on this observation. What is the implication for such different subcellular localisation? Are, for instance, post-translation modifications or trafficking throughout the cells different in the two subsets of cells? (Figure 8)</p><p>6. In multiple parts of the manuscript the authors hint at the likelihood of a cross-talk between the two identified signaling pathways, as these may well be co-responsible for the inflammatory phenotype. This is for instance the case when they show that treating embryos with a PKC inhibitor ameliorates the epidermal phenotype but only slightly the inflammatory phenotype. This is an interesting observation, but to this reviewer the authors failed to adequately discuss it both throughout the Results section and in the discussion.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66596.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential Revisions:</p><p>Having conferred, we all agree that the paper is of interest and very thoroughly done regarding most aspects of the paper. The main things we would like you to address are the following:</p><p>1. Test whether the inflammatory response is a downstream consequence of poor epithelial barrier function, due to the primary epidermal phenotype. This seems to bear out in your experiments but could be addressed with dextran permeability or other approaches.</p></disp-quote><p>We have tested this using fluorescein dextran and methylene blue permeability assays (Zhang, J et al., (2015) Exp Dermatol, 24: 605-610; Richardson, R., et al. (2013) The Journal of Investigative Dermatology, 133(6), 1655–1665). Whilst larval fin wounds show strong uptake of the dyes, we were unable to show robust staining in <italic>hai1a</italic> mutants. This data has been added as Figure 9 – —figure supplement 2. The lack of overt dye penetration made it difficult to draw conclusions from this as it is still possible there is permeability problems, just that we cannot detect it through these assays. We think more pertinent was the fact that we can rescue the epithelial defects robustly (eg with MAPK or PKC inhibition) without completely rescuing the inflammation phenotype, which you would expect if inflammation was purely a consequence of epithelial defects. Finally, new data added in response to a request by reviewer #2 has shown that the increase in Ca<sup>++</sup> and H2O2 occurs very early, prior to epidermal phenotypic presentation (New panels 1L and 3H). As these are well described pro-inflammatory drivers in zebrafish, we believe this adds to the case that the inflammation is, to some extent, independent of the epithelial defects. We thus think it unlikely that inflammation in <italic>hai1a</italic> is solely due to epithelial defects. HOWEVER, there is clear evidence from us and others that PKC and MAPK activation can also promote inflammation. We have added remarks on this to the discussion.</p><disp-quote content-type="editor-comment"><p>2. Address if the cell motility phenotype really lies downstream of DAG or is in a parallel pathway.</p></disp-quote><p>We have used a GFP-tagged PKCδ construct (Sivak, et al. (2005). Dev Cell, 8(5), 689-701) to show that PKC is relocated to plasma and nuclear membranes in <italic>hai1a</italic> from a homogeneous cytoplasmic distribution in WT (new panels 7B and Figure 7 – —figure supplement 1). This relocation assay is commonly used for demonstrating increased DAG in cells, as the activity of PLC cleaves PIP2 and increases DAG levels in the membranes. In addition, we have previously show that Gq inhibitors rescue the epithelial phenotype, which would be expected to block PLC activity and thus reduce IP3 and DAG levels, whilst PMA phenocopies the epithelial defects. Finally, inhibition of the DAG receptor, PKC, also strongly rescues the epithelial defects. Thus, these four independent experiments make a strong case for DAG contributing to the epithelial phenotype.</p><disp-quote content-type="editor-comment"><p>3. The paper is generally well-written but quite long. Please consider editing for conciseness and brevity.</p></disp-quote><p>Agreed. We apologise for the initial length of the manuscript. We have rationalised and streamlined the introduction and discussion to improve clarity and conciseness. We have shortened the Introduction from 781 words to 540, whilst the Discussion has been revised from 1578 to 1307 words yet has also incorporated the more detailed discussions on the topics required by the reviewers. We think the new flow has made it much clearer and improved readability. We have removed the emphasis on tissue damage in the discussion as suggested by Reviewer 3. We are also now under the <italic>eLife</italic> 5000-word recommendation for Research Articles.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. Are the epithelial cells really more motile or is the primary cause that they no longer act collectively together like an epithelium, and migrate because of this?</p></disp-quote><p>It’s difficult for us to say at this point. The extent of active cytoskeletal rearrangement in <italic>hai1a</italic> mutants has never been directly assessed as far as we are aware, but RSK is known to activate GEFs such as LARG (see discussion). Further it is known that <italic>hai1a</italic> mutants have increased MMPs (LeBert, et al. (2015). Development 142(12), 2136–2146). Our data and videos certainly show loss of adherens junctions and cells migrate over each other which has prompted us to label this behaviour simply as mesenchymal. We point out that this is unlikely to be due to a full EMT process as our previous analysis failed to show LOSS of E-Cadherin levels, rather just relocation. This is consistent with the know role of RSK in p120 phosphorylation.</p><disp-quote content-type="editor-comment"><p>2. You mention a comprehensive proteomic screen yet there is no real reference to this in how you went about it in your experiments. Were the proteomics results, in fact, used? The rationale seems to go without it. If not, do you need to include it?</p></disp-quote><p>This 2D gel proteomic screen identified Peroxiredoxin-4 as having altered pI, and this was our critical inroad into the mechanism by highlighting likely H2O2 changes. We have now included the full reports for this screen in supplementary data for the readers.</p><disp-quote content-type="editor-comment"><p>3. Your analysis frequently depends on inhibitors. While you explain that sometimes morphants didn't work, I think you need to at least change the language in your results to suggest, as you could be having some off-target effects with drugs like U0126 and others.</p></disp-quote><p>We have now added qualifiers to our conclusion statements throughout.</p><disp-quote content-type="editor-comment"><p>4. Throughout, I found that the paper was logically ordered, and the results were very clear. However, I did find that the introduction and the discussion of the pathway could be more concise and clearer. It may be useful here to use a schematic to show the pathway implied before and then how your findings changed that, which could go at the beginning of the paper so people know where you are going.</p></disp-quote><p>Yes – agreed. It was quite impenetrable. Sorry! We have re-written the introduction and discussion to streamline and include only the relevant background information. I think this has made the main contributions of the paper to the field much clearer and more accessible. I believe now that the simplified introduction has obviated the need for a schematic in the introduction, but happy to draft one if you think it is still required above the summary diagram Figure 11. The verbosity of the paper was a common theme from the reviewers, and we are happy to take further reviewer and editor guidance on this if our edited version is still deemed to be too long. We are now under the 5000 suggested length for <italic>eLife</italic> Research Articles.</p><disp-quote content-type="editor-comment"><p>5. Throughout, you mention the n in the figure legends but don't refer to what the n is-is it total embryos used for each condition or experimental numbers?</p></disp-quote><p>Generally, n was number of embryos for each condition, except where we have counted a number of cells in a range of embryos, where we have been explicit about this in the figure legend. We have now added this explanation to the Materials and methods.</p><disp-quote content-type="editor-comment"><p>6. What are the differences between ERK activation in nucleus and cytoplasm?</p></disp-quote><p>Activated pERK1/2 are known to have phosphorylation targets at the membrane (eg EGFR), in the cytoplasm (eg p90RSK) and in the nucleus (eg transcription factor Ets). The mechanisms regulating sub-cellular localisation, and thus availability of pERK for phosphorylating substrates, is a large field of its own, but levels of scaffolding proteins, activating kinases and phosphorylation of nuclear pore proteins likely contribute (Pouysségur J, Volmat V, Lenormand P. Biochem Pharmacol. 2002 Sep;64(5-6):755-63.). We suspect that there will also be other ERK mediated changes in different cell types in <italic>hai1a</italic>, including modulation of other cytoplasmic targets and transcriptional effects. We have added a sentence to the discussion highlighting this.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. It is important to directly link the hai1-matriptase system to DAG to implicate that arm of the signaling cascade. Is it possible for the authors to show the elevated levels of DAG in the hai1 mutant or to inhibit DAG in the hai1 mutant background by chemical or genetic means?</p></disp-quote><p>As described above in the response to Essential Revision #2, we have now included data on the GFP-tagged PKCδ construct (Sivak, et al. (2005). Dev Cell, 8(5), 689-701) to show that PKC is relocated to plasma and nuclear membranes in <italic>hai1a</italic> from a homogeneous cytoplasmic distribution in WT (new panels 7B and Figure 7 – —figure supplement 1). This is a common assay for increased DAG levels in cells.</p><p>We now have 4 main results supporting our case that DAG contributes to the cell motility phenotype of <italic>hai1a</italic> mutants.</p><p>a. PKCδ-GFP relocates to nuclear and plasma membranes from the cytoplasm in <italic>hai1a</italic> as expected for increase in cellular DAG levels.</p><p>b. Gq, activator of PLC, rescues the epithelial defects, whilst the IP3R inhibitor does not. By elimination this suggests the other product of PLC activity, DAG, as responsible for the epithelial defects</p><p>c. Inhibition of the DAG receptor, PKC, rescues the epithelial defects</p><p>d. A DAG mimic, PMA, phenocopies the hai1a epithelial phenotypes.</p><disp-quote content-type="editor-comment"><p>2. To support their conclusion that the two arms of the signaling cascade are causally linked with the phenotypic manifestation, the increase in H2O2 levels, Ca++ flashes, the activation of NfkB signaling, nuclear localization of phosphoRSK need to be shown just before the phenotype arise, if not for all at least for pRSK and NFkB activation. It would also be pertinent to block the signaling arms (using inhibitors) before the phenotypic onset and after the phenotype sets in to delineate the requirement of the cascade for phenotypic manifestation versus phenotypic maintenance.</p></disp-quote><p>We have now included early staining and videos at 15-17hpf to look at the levels of these signals prior to phenotype presentation. These analyses required us to genotype embryos after staining and imaging as the epithelial defects were not apparent at this early stage. We have found that prior to phenotype manifestation:</p><p>a. H2O2 is highly increased in the yolk area at 16hpf (Figure 1K-L)</p><p>b. Calcium flashes are seen at 16hpf extensively over the yolk epidermis (Video 4; Figure 3G-H)</p><p>c. Nfkb is NOT increased noticeably at 15hpf, suggesting that this might be a driver of later chronic inflammation unlike the known early role of H2O2. (Figure 4 – —figure supplement 1C-D)</p><p>d. pERK levels are increased at early stages in nascent aggregates (Figure 8 – —figure supplement 1H) and in regions prior to forming aggregates (Figure 8G)</p><p>e. Similarly, cytoplasmic levels of pRSK are increased at 17hpf in regions outside of aggregate formation (Figure 10 – —figure supplement 1A-C)</p><p>We have compared U0126 treatment from 16hpf with later treatment from 26hpf and see that the latter gives a milder rescue. We interpret this to mean that the epithelial phenotype in <italic>hai1a</italic> mutants requires sustained pERK activity (Figure 9 – —figure supplement 1K-M’).</p><disp-quote content-type="editor-comment"><p>3. Given that the Hai1-Matriptase system activates this bipartite signaling cascade to control the inflammation and epithelial cell motility, it is intriguing that the hai1 alleles are viable. How do authors explain the resolution of phenotype and survival of animals to adulthood? This aspect must be discussed.</p></disp-quote><p>Apologies for the confusion here, the strong alleles (<italic>fr26, ti257, t419)</italic> are early lethal and die within the first week. The mild allele <italic>hi2217</italic> is semi-viable to a highly variable extent. We used to see adult survival, but less so know, and it is common for them to die at 1 month. We think that there are modifiers that alter severity. The reason some mild <italic>hai1a<sup>hi2217</sup></italic> mutants survive has been recently determined to be due to cell extrusion and entosis (see Armistead et al. 2020). We have clarified this in the introduction.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>The main problem with this manuscript lies not with the experimental data but instead with the way it is presented. The manuscript is far too long and the figures too numerous. Much of the data could be removed or moved to supplementary and the paper should be condensed down to five or six figures.</p><p>As indicated above, a major concern is that the relevance of these findings to a tissue damage response – which is openly stated in the manuscript's title – are not clear or at least not clearly supported by the data. The title of the paper is misleading as the authors don't show any real evidence that this is a true tissue damage response or show any data on how matriptase is activated (or Hai1a might be inactivated) downstream of damage/wounding. Overexpression of matriptase (or inactivation of Hai1a) leads to many of the same biological outcomes as wounding but claiming this is a tissue damage response without directly linking it to damage is a step too far and unnecessary. This message should be toned down throughout the manuscript and the title should be changed.</p></disp-quote><p>This is quite a reasonable suggestion, and I did get a little carried away with this topic. So I have changed the title and significantly reduced the emphasis on tissue damage. I point out however that we are not the first to make this claim about what the phenotypes of zebrafish <italic>hai1a</italic> represent, with the Coughlin lab concluding that these appear as tissue injury responses (Schepis, A., et al. (2018). J Cell Biol, 217(3), 1097-1112), whilst our original analysis of the <italic>hai1a</italic> mutant also discussed the phenotype in the context of wounding (Carney, T. J., et al. (2007). Development, 134(19), 3461-3471). I have referenced the Schepis paper specifically where I have briefly alluded to this topic. However, I fully agree that the discussion inappropriately overemphasised this. I hope this reads far more balanced now.</p><disp-quote content-type="editor-comment"><p>Despite the manuscript being overly long, in multiple instances, the authors fail to adequately discuss the broader meaning of their findings, The discussion is far too long and reads more like a literature review rather than an attempt to extend their discoveries to other systems or contexts. The authors need to be much more concise throughout. If the authors can fix these problems with the structure and presentation of the paper as well as address the comments below then I would support publication.</p><p>1. To this reviewer, the authors did not clearly characterise the &quot;inflammatory phenotype&quot;, nor explain the relevance of the &quot;epidermal phenotype&quot; for the fully-formed organism. As a criticism to the conclusion that neutrophils are highly migratory in Hai1a mutants, in comparison to WT, has it been considered that the increase in cell speed could be due to the lack of spatial constraint (which is instead present in WT, since neutrophils are moving within the vasculature?). Furthermore, is the lack of directionality (figure 1D) a real surprise, or a mere consequence of the lack of imposed stimuli (e.g. a wound) in these settings?</p></disp-quote><p>We think it unlikely that the epidermis constrains neutrophils or retards their migration to any appreciable extent. Evidence for this can be seen in the WT fin wounding in Video 2, where at 178mins, a neutrophil appears from the anterior and tracks under the epidermis towards the wound with great speed. It is difficult to envisage that the epidermis this far from the wound is compromised and permitting increased neutrophil speed. Further to this reviewer’s concerns, we looked at 2 mutants with subepidermal blistering of the fin folds immediately under the posterior cardinal vein (<italic>pif</italic> and <italic>nel</italic>). This blistering alone did not induce extravasation of neutrophils out of the vasculature, except when the fin degenerated to cause a localised wound, towards which they migrated very specifically (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>).</p><fig id="sa2fig1"><label>Author response image 1.</label><caption><title>Epidermal detachment does not lead to increased neutrophil motility.</title><p>A-E: Lateral confocal images of the tails of 36hpf WT (A), <italic>hai1a<sup>hl227</sup></italic> (B), <italic>pif<sup>tm95b</sup></italic> (C), and <italic>nel<sup>tq207</sup></italic> (D-E) immunofluorescently stained for Mpx (Green) and superimposed on the DIC channel. The sub-lamina densa blistering of the fins in <italic>pif</italic> and <italic>nel</italic> mutants does not lead to the epidermal inflammation seen in <italic>hai1a</italic> mutants. Only where there is epidermal damage and degeneration are neutrophils seen outside the vasculature, and then they only migrate to the damage site (E, red arrowhead). Scale bar A = 100μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66596-resp-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>2. &quot;We noted that again, whilst there was brief local recruitment in the mutant, more distant neutrophils appeared apathetic to the wound and remained migrating randomly, unlike in wild-type where neutrophils were recruited from a great distance and tracked to the wound with high directionality&quot;. The distance traveled by neutrophils cannot be appreciated from figures 1F-G.</p></disp-quote><p>We have now included graphical representation of this data as a new panel (Figure 10 – —figure supplement 1D).</p><disp-quote content-type="editor-comment"><p>3. Using the stain pentafluorobenzenesulfonyl fluorescein (PFBSF) (Maeda et al., 2004), we observed significantly higher levels of H2O2 in the trunk and tails of hai1a mutants at 24 and 48hpf (Figure 1G-I, Figure S1G-H). These figure references are misplaced.</p></disp-quote><p>Apologies. These figure references have now been corrected.</p><disp-quote content-type="editor-comment"><p>4. In figure 4, the authors demonstrate that Hai1a mutants have hyperactivation of the NFkB signalling (Figure 4B), and that this is due to H2O2, as it can be rescued by treatment with a DUOX morpholino (Figure 4K). Strangely however, they also found that inhibition of calcium flashes via 2-APB only very moderately ameliorates the NFkB overactivation (Figure S4F-G). If DUOX is activated by Calcium, shouldn't the two treatments (DUOX morpholino and 2-APB treatment) yield the same response? How do the authors explain this observation, and fit it within their working model?</p></disp-quote><p>Our model (Figure 11) also includes activation of Duox by PKC which has been described previously (Rigutto et al. JBC 284(11), 6725-6734). This reconciles the ability of PMA to generate H2O2, (Figure 6M) and NfkB (Figure 6U) but not calcium (Figure 6Q, S). It also explains why IP3R inhibition has a strong effect on H2O2 but only a moderate effect on NfKb levels (Figure 3J, Figure 4 – —figure supplement 1I). We have included this in the discussion.</p><disp-quote content-type="editor-comment"><p>5. The authors briefly mention that in a subset of cells (TP63 +ve cells), pERK was observed both in the nucleus and cytosol, while in another subset of cells (peridermal cells) it was only observed in the nucleus. As in other instances throughout the manuscript, the authors fail to further comment on this observation. What is the implication for such different subcellular localisation? Are, for instance, post-translation modifications or trafficking throughout the cells different in the two subsets of cells? (Figure 8)</p></disp-quote><p>Reviewer #1 also had this query and I refer to the answer above. In truth, we have no data on this at all. We note that there are differences in reliance on ErbB2 function between the cells and this may translate to different pERK behaviours, but this is just a guess. Briefly there are transcriptional, membrane and cytoplasmic targets of pERK phosphorylation. Subcellular localisation of pERK, and thus accessibility to substrates, is determined by amount of scaffolding proteins, activating kinases and phosphorylation of nuclear pore proteins. The full picture of how pERK is localised within the cell is quite poorly understood (Pouysségur J, Volmat V, Lenormand P. Biochem Pharmacol. 2002 Sep;64(5-6):755-63.). Recently calcium levels are described to alter pERK subcellular localisation (Chuderland D, Marmor G, Shainskaya A, Seger R. Cell Physiol Biochem. 2020 May 12;54(3):474-492). We have now added comments on this to the discussion, but I have to confess that at his point, we are unclear on what this means in terms of the biology, beyond the RSK target.</p><disp-quote content-type="editor-comment"><p>6. In multiple parts of the manuscript the authors hint at the likelihood of a cross-talk between the two identified signaling pathways, as these may well be co-responsible for the inflammatory phenotype. This is for instance the case when they show that treating embryos with a PKC inhibitor ameliorates the epidermal phenotype but only slightly the inflammatory phenotype. This is an interesting observation, but to this reviewer the authors failed to adequately discuss it both throughout the Results section and in the discussion.</p></disp-quote><p>We have now discussed this in the discussion, and integrated this into our model clearly, justifying it through referring to our own observations and also by referencing the literature. We have now also included reference to (Feng et al. (2010) PLoS Biol, 8(12), e1000562), which showed that RasV12 transformed zebrafish keratinocytes also show increased hydrogen peroxide release and inflammation.</p></body></sub-article></article>